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Abstract
Large-scale biological and medical data is continuously produced, making by
now Life Sciences part of Big Data sciences. Such data contain acute information
that can enable a better understanding of the molecular mechanisms behind biolog-
ical systems. This information is essential for the progress in the diagnosis and the
treatment of diseases. Bioinformatics and Computational Biology are the disciplines
dedicated to the organization, analysis, and interpretation of the data produced by
Life Sciences. Indeed, biological data mining is complicated by the heterogeneous
and complex nature of the data, that are very dependent on the specific experimental
details. The complexity and variety of biological problems require the continuous
design, implementation, and application of new methods and algorithms.
This thesis deals with one specific complex biomedical problem, i.e. the lower
than expected probability of cancer patients develop some central nervous system
(CNS) or neurological disorder and viceversa. This condition is known as inverse
comorbidity. At the medical level, a better understanding of the connections and
interactions between cancer and neurological disorders could potentially improve the
quality of life and healthcare outcome of millions of people worldwide. Even if this is
a well characterized phenomenon, based on solid population and epidemiological
studies, very little is known about the molecular basis of inverse comorbidity.
The principal objetive of this thesis is to unveil the biological mechanisms behind
cancer-CNS inverse comorbidity. We have developed three computational strategies
based on machine learning and pattern recognition techniques to address specific
problems related with cancer and CNS disorders inverse comorbidity. In the first
method we advanced a novel data mining approach to compute transcriptomic meta-
analyses between some types of cancer and CNS disorders. Using gene expression
data, our principal idea was to test whether there was a significant co-occurrence
between genes that were up-regulated in cancer and down-regulated in CNS disorders,
v
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and the other way around. The main result of this study was the detection of a signifi-
cant overlap between the genes up-regulated in CNS disorders and down-regulated
in cancers, and viceversa. In addition, a similar outcome was observed at the level
of general functions and biological pathways. In other words, this first development
set the basis for the study of specific genes and pathways, the up-regulation of which
could increase the incidence of CNS disorders and simultaneously reduce the risk of
developing cancer, while the down-regulation of another set of genes and pathways
could contribute to a decrease in the incidence of CNS disorders while increasing
cancer risk.
In the second method we presented a novel computational approach inspired by
Simulated Annealing to study the stability of protein interaction networks in cancer
and CNS disorders. Molecular systems are organized as networks of interactions. In
this case we took advantage of protein–protein interaction networks (PPINs), includ-
ing information on physical interactions between proteins that form active molecular
complexes. In this manner, we integrated gene expression data with PPINs to study
the differences in terms of network organization rather than at the level of individual
genes. Our proposal was based on the combination of large-scale biological data sets
on gene expression data and PPINs. With this information we observed that CNS
disorders are characterized by a higher stability while networks informed with cancer
gene expression data tend to be less stable than the corresponding controls. Moreover,
this instability in the network seemed to increase as cancer evolves.
The third work described a novel methodology inspired by the human reasoning,
and based on the combination of supervised and unsupervised classification methods
(Self-Organizing Maps and K-Means), and clustering validity indices. Previous studies
indicate that cancer related genes tend to encode central hubs within the PPIN, and
other authors have shown that cancer related proteins have a much stronger protein–
protein interaction density than control proteins in the whole human interactome.
With this motivation we examined critically the organization of protein networks
around cancer related proteins (CRPs), and compare it with the one of proteins related
with neurological disorders (NRPs) pursuing the inverse comorbidity theory that relates
these complex disorders. Two features were defined, i.e. dex and partial_nE, that
were capable to categorize in different groups proteins related to cancer or CNS
disorders, corresponding with clusters with high or low feature values. We observed
that relevant clusters enriched in the cancer-related proteins include very connected
proteins, while clusters enriched in the proteins related with neurological disorders
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Acknowledgements
encompass less connected proteins. This type of strategy is new in the area of gene
expression/protein network analysis applied to the relation between diseases, where
it might potentially open the field to new applications.
In conclusion, this thesis constitutes a new and concerted effort to study the
molecular basis of inverse comorbidity, including three computational methodologies
addressing three specific problems in the field. Our results demonstrate that the data
mining and machine learning techniques, that have been the drivers in this research,
are adequate methodologies to progress in the field of inverse comorbidity, as well as
the potential of their application to other problems in biomedicine.
vii

Resumen
La cantidad de datos biológicos y médicos que se produce hoy en día es enorme, y
se podría decir que el campo de las ciencias de la vida forma parte ya del club del Big
Data. Estos datos contienen información crucial que pueden ayudar a comprender
mejor los mecanismos moleculares en los sistemas biológicos. Este conocimiento
es fundamental para el progreso en el diagnóstico y en el tratamiento de las enfer-
medades. La Bioinformática, junto con la Biología Computacional, son disciplinas que
se encargan de organizar, analizar e interpretar los datos procedentes de la Biología
Molecular. De hecho, la complejidad y la heterogeneidad de los problemas biológicos
requieren de un continuo diseño, implementación y aplicación de nuevos métodos
y algoritmos. La minería de datos biológicos es una tarea complicada debido a la
naturaleza heterogénea y compleja de dichos datos, siendo éstos muy dependientes
de detalles específicos experimentales.
Esta tesis se basa en el estudio de un problema biomédico complejo: la menor
probabilidad de desarrollar algunos tipos de cáncer en pacientes con ciertos trastornos
del sistema nervioso central (SNC) u otros trastornos neurológicos, y viceversa. De-
nominamos a esta condición como comorbilidad inversa. Desde el punto de vista
médico, entender mejor las conexiones e interacciones entre cáncer y trastornos
neurológicos podría mejorar la calidad de vida y el efecto de la asistencia médica
de millones de personas en todo el mundo. Aunque la comorbilidad inversa ha sido
estudiada a nivel médico, a través de estudios epidemiológicos, no se ha investigado
en profundidad a nivel molecular.
El objetivo principal de esta tesis es explorar los mecanismos biológicos que hay
detrás de la comorbilidad inversa entre cáncer-enfermedades neurológicas. Hemos
desarrollado tres metodologías computacionales basadas en técnicas de aprendizaje
automático y reconocimiento de patrones para abordar problemas específicos rela-
cionados con la comorbilidad inversa. En el primer método proponemos una nueva
ix
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estrategia propia de minería de datos para llevar a cabo un meta-análisis de expre-
sión génica entre ciertos tipos de cánceres y enfermedades neurológicas. A partir de
datos de expresión de genes, evaluamos si la comorbilidad inversa se relaciona a nivel
molecular con una co-ocurrencia significativa de genes que están sobre-expresados
en cáncer y sub-expresados en las enfermedades neurológicas, y viceversa. El re-
sultado principal de este estudio confirma la relación entre comorbilidad inversa y
patrones opuestos de expresión génica, confirmando la existencia de un solapamiento
relevante entre los genes sobre-expresados en los trastornos neurológicos y aquellos
sub-expresados en cáncer, y a la inversa. Estos patrones génicos inversos se reflejan de
modo significativo a nivel de rutas biológicas. Es decir, este primer estudio representa
la base para el estudio de genes y rutas biológicas específicas, en el cual los genes
sobre-expresados podrían aumentar la incidencia de trastornos neurológicos, y si-
multáneamente, disminuir el riesgo de desarrollar cáncer. Asimismo, la sub-expresión
de algunos conjuntos de genes y rutas biológicas podrían contribuir a la disminución
de la incidencia de enfermedades neurológicas, aumentando así el riesgo de cáncer.
En el segundo trabajo presentamos una metodología computacional nueva inspi-
rada en el "Enfriamiento Simulado" (del inglés Simulated Annealing) para estudiar la
comorbilidad inversa entre cáncer y enfermedades del SNC. En este caso utilizamos
aproximaciones relacionadas con la teoría de redes, puesto que los sistemas molecu-
lares están organizados como redes de interacción. En este caso, utilizamos las redes
de interacción de proteínas (PPINs), que incluyen información de las interacciones
físicas entre proteínas que forman complejos moleculares, junto a datos de expresión
de genes con los que los integramos para analizar la influencia de la expresión génica
propia de cada enfermedad en la organización de la red de interacciones. Observamos
que las enfermedades del SNC están caracterizadas por una estructura de red que
se puede interpretar de mayor estabilidad (es decir, estado de la red que no se altera
significativamente, aun cuando las propiedades fundamentales cambian o se intro-
ducen perturbaciones) que sus correspondientes controles, mientras que las redes
anotadas con la expresión de genes de cáncer tienden a ser menos estables que sus
correspondientes controles. Además, esta inestabilidad en la red parece que aumenta
con la progresión del cáncer.
El tercer trabajo describe una metodología nueva inspirada en el razonamiento
humano, y se basa en la combinación de técnicas de clasificación no supervisadas
(SOM y K-Means). A partir de los principales resultados obtenidos a partir del segundo
método, examinamos de manera crítica si las proteínas relacionadas con cáncer
x
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(CRPs) tienden a estar más o menos conectadas. Asimismo, analizamos también si las
proteínas relacionadas con trastornos neurológicos (NRPs) tienen un comportamiento
opuesto al que muestran las CRPs, siguiendo así la teoría de la comorbilidad inversa.
Definimos dos atributos, dex y local_nE, para categorizar y diferenciar en diferentes
grupos proteínas relacionadas con cáncer o enfermedades neurológicas, incluyéndose
éstas en conjuntos con mayor o menor valor de los atributos definidos. Observamos
que los grupos (clusters) más relevantes enriquecidos en CRPs incluyen proteínas
altamente conectadas, mientras que grupos enriquecidos en NRPs incluyen proteínas
menos conectadas entre sí. Este tipo de estrategia es nueva en el área de estudios en
la cual se combinan expresión de genes y redes de interacción de proteínas aplicados
a la relación entre enfermedades complejas, donde puede abrir el campo a futuras
nuevas aplicaciones.
Esta tesis constituye un trabajo de investigación nueva, original y multidisciplinar
en el que se estudia la base molecular de la comorbilidad inversa, incluyendo tres
metodologías que abordan y proponen soluciones a tres problemas específicos en
el área. El diseño, desarrollo y aplicación de estas metodologías tienen su eje en los
campos de la minería de datos y aprendizaje automático, y los resultados obtenidos
son significativos en los campos de la comorbilidad inversa y la biomedicina.
xi
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1 Introduction
1.1 Preface
The development of large-scale genomics and post-genomics methods, large
biological databases and new statistical approaches in combination with adequate
data mining and machine learning techniques allows us to examine for the first
time human complex disorder relationships. There is an ongoing debate about the
associations between some kinds of cancer and neurological disorders or central
nervous systems (CNS) disorders. Certain combinations of cancers and CNS disorders
co-occur by chance less often than expected, while others co-occur by chance more
often than expected. In medicine the co-occurrence of several diseases is known as
comorbidity. This is well stablished at the medical level and is part of the medical
protocols. But it is relatively unexplored compared to individual diseases.
The sequencing of the entire human genome allows to identify genes that are
causally linked to some diseases. Toward a therapy or cure, whether a particular gene
is expressed or not and how the gene functions in normal and affected cells must
be understood. The fact is that there is a complex molecular process behind each
disease, and it requires an understanding of molecular genetics and the molecular
basis of the disease. Each disorder can be considered as having a particular molecular
mechanisms, in which some processes underlying normal mechanisms are perturbed
and many others are undamaged. The phenomenon of comorbidity often suggests
that the molecular mechanism for different disorders intersect. These intersections
could be informative about underlying mechanisms and can shed some light on many
mechanisms underlying both disorders. In particular, understanding intersections or
differences between different diseases might be the key to finding novel treatment for
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both types of conditions, for instance thanks to drug repurposing or repositioning.
Epidemiological and clinical population studies can reveal statistical associations
between complex disorders. Bioinformatics, data mining and machine learning tech-
niques, and the integrative analysis of massive genomic data, offer an interesting
avenue for the understanding of comorbidities while studying, for instance, the par-
ticipation of genes at the level of biological pathways or networks. Molecular biology
can address the molecular mechanisms behind these clinical conditions and might
be useful facilitating new treatments and novel drug development, and might help to
improve diagnoses and prognosis.
1.2 Evolution of bioinformatics and machine
learning
In the advent of high-throughput genomics, datasets need to be managed and
interpreted. Bioinformatics and computational biology are the disciplines that en-
compass the analysis and interpretation of this data, the modeling of biological phe-
nomena, and the development of algorithms (Thampi, 2009). This domain is a multi-
disciplinary field that includes molecular evolution, biological modeling, biophysics,
and systems biology among others.
Despite the fact that bioinformatics seems a recent field of study is in the 1960s
when it began and coincided with the rise of molecular evolution. Early contributors
to this field include Margaret O. Dayhoff, Walter M. Fitch, Russell F. Doolittle, Richard
V. Eck, and Robert S. Ledley. It was in 1962 that Margaret O. Dayhoff wrote Comprotein,
the first algorithm to determine the primary protein structure (Dayhoff and Ledley,
1962). Few years later, a collaboration between Richard V. Eck, Robert S. Ledley, and
others produced the first computer-based collection of protein sequences (Dayhoff
et al., 1965) called The Atlas of Protein Sequence and Structure. It was the first public
comprehensive, computerized, and publicly available database of protein sequences,
and it has been used as a model for many molecular databases, such as GenBank1.
This premier database was an essential tool for the development of molecular biology,
molecular evolution, and bioinformatics. Concurrently, advances within the structural
1GenBank® is the National Institute Health genetic sequence database, an annotated collection
of all publicly available DNA sequences.
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biology field were fundamental. First methodologies to analyze and interpret biologi-
cal data derived from X-ray crystallography to obtain macromolecular structures were
developed [for a review see (Cassiday, 2014)]. In an era when computers were not
needed to manage data, bioinformatics started bringing a number of fields together
in a common pursuit (Doolittle, 2010). Soon, computers started to become more and
more important in the handling and analysis of biological data in general.
Figure 1.1: The IBM 7090 computer Margaret O. Dayhoff used in her early work
(Hagen, 2000).
A few years later, Dayhoff started analyzing protein evolution using computational
methods (Dayhoff, 1969). Meanwhile, Walter M. Fitch was developing algorithms
and practical methods for phylogenetic tree construction (Fitch, 1970) and pioneer-
ing statistical approaches to sequence comparison (Fitch, 1970) and phylogenetic
analysis (Fitch and Margoliash, 1967). He also introduced the covarion approach
when studying gene evolution (Fitch, 1976). The principal research interest of Russell
F. Doolittle was the evolution of protein structure (Doolittle et al., 1962; Doolittle
and Blombaeck, 1964; Doolittle et al., 1967). His work showed how early amino acid
sequence comparisons started and revealed a great deal about evolution and how
computers started becoming necessary when the number of known sequences began
to grow exponentially (Doolittle, 2010). Thus far, publications in this interdisciplinary
field have been constant. Moreover, from genomic sequences through proteins, bioin-
formatics has been applied in various areas, such as molecular medicine, personalized
medicine, preventive medicine, gene therapy, drug development, antibiotic resistance,
comparative studies, and gene therapy between others.
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The first genomes completely sequenced corresponded to bacteria and budding
yeast [for a review see (Binnewies et al., 2006)]. The first bacterial genome sequenced
was the Haemophilus influenzae (Fleischmann et al., 1995), and the budding yeast
Saccharomyces cerevisiae represented the first eukaryotic genome sequenced (Fraser
et al., 1995). These discoveries led to a fast development of new technologies that
made easier and cheaper to do sequencing, and the number of complete genome
sequences started growing rapidly. It was in 1990 when the Human Genome Project2
got underway, and since then, a huge amount of biological data has been generated.
Thenceforth, the development of tools and methods capable of transforming all this
complex data into biological knowledge has been urgently needed (Larrañaga et al.,
2006).
Therefore, ways to advance computational methodologies to analyze high through-
put data in genomics and proteomics have been extensively studied and are essential
in understanding biological mechanisms (Liu et al., 2013a). Thus, machine learning
and related techniques such as Markov models, decision trees, supporting vector
machines, and neural networks have been increasingly used to solve problems in
genomics and systems biology. Markov models have been widely used solving differ-
ent biological sequence analysis problems such as pairwise and multiple sequence
alignments, gene annotation, classification or similarity search (Yoon, 2009). For
instance, they have been used in protein secondary structure prediction (Won et al.,
2007), gene prediction [for a review see (Wang et al., 2004)], pairwise and multiple
sequence alignment [for instance, ProbCons multiple sequence aligner which uses
hidden markov models to specify the probability distribution over all alignments
between a pair of sequences (Do et al., 2005)], homologous protein or nucleotide
sequence identification [see the widely used HMMER approach (Eddy, 1998), and for
a review see (Durbin et al., 1999)], and many others. Supporting vector machines are
usually used in the classification and prediction of the biological data since biological
databases increase, and automatization of the classification process is needed (Yang,
2004). For example, they have been widely used in protein function prediction [for a
review see (Bernardes and Pedreira, 2013)], transcription factor binding prediction
(Holloway et al., 2005), pairwise homology [for a review see (Saigo et al., 2011)], or gene
expression data classification (Vanitha et al., 2015). Among decision tree algorithms
ID3 (Quinlan, 1986) and its successor C4.5 (Quinlan, 1993), and CART (Breiman et al.,
2The Human Genome Project is an international research project to determine the sequence of
the human genome and to identify the genes it contains.
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1984) are probably the most popular,and they have been applied extensively in compu-
tational biology in sequence annotation, as biomarker discovery, regulatory networks,
or structural biology among others.The ability of neural networks to learn complex
functions from large amounts of data, also makes them an ideal tool to aid in the
solving biological problems such as protein three dimensional structure prediction
[for a review see (Wu and McLarty, 2000)], sequence feature analysis and classification
(Wu, 1997), or coding region recognition and gene identification [for a review see
(Rozenberg et al., 2011)].
Interestingly, based on the list of the 100 most highly cited papers of all time
(Van Noorden et al., 2014), 7 out of 100 works correspond to bioinformatics, and
the CLUSTAL W (Thompson et al., 1994), BLAST (Altschul, 1997) and, CLUSTAL X
(Thompson, 1997) machine learning methods appear in the 10th, 12nd, and 28th
positions with 40,289, 38,380, and 24,098 cites respectively. In summary, it can be
said that machine learning and biology have been feeding each other; and improved
computational strategies are necessary to both fields advance.
Machine learning is of huge relevance in bioinformatics and in biomedical science
more generally (Jensen and Bateman, 2011). The relationship between biology and
the field of machine learning has been long and complex (Tarca et al., 2007). The
perceptron algorithm (Rosenblatt, 1958) was the first technique in machine learning
that was used to try to model actual neuronal behavior; the field of artificial neural
network design grew from this attempt. This algorithm was first used in the molecular
biology in the analysis of translation initiation sequences in Escherichia coli (Stormo
et al., 1982). Unsupervised and supervised machine learning techniques have also
been widely used in numerous life science applications. For instance, using gene
expression data, patients can be classified in different clinical sets, and new disease
groups can also be identified (Perou et al., 1999; Alon et al., 1999; Alizadeh et al., 2000;
Ross et al., 2000). Using evolutionary information from multiple sequence alignments
to predict protein secondary structure (Rost and Sander, 1994) is another example.
A plethora of biological and medical research problems can be analyzed by inte-
grating advanced machine learning and computational modeling. But rather than
focusing on components in isolation (i.e., genes or proteins), the study of the inter-
action between individual components can help in understanding how biological
systems behave. Biological systems can be described as complex networks of biolog-
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ically relevant entities (D’Alche-Buc and Wehenkel, 2008). The principal objective
of Systems Biology is to understand the network behavior and the dynamic aspects,
which requires the use of mathematical modeling. Machine learning is one of the
drivers of progress in this context. Systems Biology cares about the study of the sys-
tems of biological components (i.e., molecules, cells, organisms or entire species).
These systems are dynamic and complex, and their behavior is not trivial to predict
from their individual components. Systems Biology consists in the development of
mathematical and computational models to describe these dynamical systems. For
instance, discovering topological and other characteristics of metabolic networks
(Jeong et al., 2000) or analyzing how genetic interactions combining with environ-
mental factors organize development and response to a disease (Bruggeman and
Westerhoff, 2007). Also, biological networks have been modeled in multiple works:
Geurts et al. (2007) have proposed a method based on kernel trees to predict links in
protein–protein interaction networks and enzyme networks.
An interesting point in the evolution of bioinformatics is that in 1951 Alan Turing
contributed to mathematical biology with a publication in which he developed the
reaction–diffusion theory. This became one of the basic models of theoretical biology
and is also considered a foundation of chaos theory (Turing, 1952). This work led to
the development of a whole new area of research related to the creation of patterns in
nature. Turing discovered, at least in theory, a system based on two molecules that
could create patterns of spots or stripes if these molecules were diffused and interacted
chemically in a certain way. This theory was accepted as an explanation of simple
patterns, such as zebra stripes or the ridges that are formed in sand dunes. Slowly,
researchers were piecing together the role of Turing systems in creating biological
structures. Interestingly, the Multicellular Systems Biology group at the Centre for
Genomic Regulation (Barcelona) coordinated by James Sharpe confirmed that fingers
and toes follow the model described by Turing theory (Raspopovic et al., 2014). This
study solves the puzzle using systems biology and by combining experimental data
and a mathematical model to show which molecules act as Turing predicted, BMT or
WNT genes [see (Sheth et al., 2012; Raspopovic et al., 2014) for more information].
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Figure 1.2: Turing system used in creating biological structures
(by ©Job Boot).
1.3 Biological concepts
Cells are fundamental building blocks of living organisms and contain different
kinds of organelles, such as nucleus, mitochondria, ribosomes, and vacuoles. The
nucleus is an essential part, housing the chromosomes that include DNA. DNA is the
hereditary material in humans and almost all the organisms that contains the genetic
instructions for the development.
In molecular biology, the central dogma is the passage of information from genes
(DNA) to proteins via RNA. Figure 1.3 shows an original 1956 depiction by Crick (1958).
Figure 1.3: An early depiction of the central dogma in molecular biology (Crick,
1958).
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The gene has been defined as "a locatable region of genomic sequence, corre-
sponding to a unit of inheritance, which is associated with regulatory regions, tran-
scribed regions, and or other functional sequence regions" (Pearson, 2006; Pennisi,
2007). In other words, genes are the blueprint for life; they tell cells what to do and
when to do it. Genes generally express their functional effect through the production
of proteins (Figure 1.3), which are essential in order to execute functions in cells.
Studying human genes can help us to understand the genetic context behind complex
disorders.
1.3.1 Gene expression and microarrays
Transcriptomics or gene expression analysis is the study of the transcriptome, the
complete set of RNA transcripts that are produced by the genome in a specific cell.
It allows the identification of genes that are differentially expressed in distinct cell
populations or in response to different drugs.
Gene expression is a two-step process in which the information encoded in the
DNA is used to codify the chain of amino acids that form a protein (Figure 1.3). The
control of gene expression causes most phenotypic differences in organisms (Ardlie
et al., 2015). Gene expression can explain differences in the phenotype, and so, in
the protein function. Because of many disease result from complex changes on the
molecular level, observations and models of these processes on the system level are
needed.
A measurement of the amount of gene product is sometimes used to infer how
active a gene is. An abnormal amount of gene product can be correlated with a deregu-
lation of the transcription that can directly cause anomalous behaviors associated with
a disease. For instance, it has been seen that TOMM34 is frequently over-expressed
in colorectal cancer tumors, and is involved in the growth of the colorectal cancer
cells (Zhang et al., 2014). Another example are the findings of Barna et al. (2008),
which demonstrate that the ability of MYC gene to increase protein synthesis, directly
augments cell size and is sufficient to accelerate cell cycle progression independently,
linking this over-expression of MYC gene with an oncogenic signal.
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Recent advances in biology have resulted in different techniques and tools to
measure gene expression called microarrays. A DNA microarray is a collection of
microscopic DNA spots attached to a solid surface. DNA microarrays are used to mea-
sure the expression levels of a large number of genes simultaneously or to genotype
multiple regions of a genome.
Microarray techniques are used in gene discovery, such as in the global descrip-
tion of genes potentially involved in developmental, physiological, and pathological
processes; gene regulation, the description of regulatory networks, based on the
assumption that genes regulated in parallel share common control mechanisms; diag-
nosis, the identification of patterns of gene expression that define disease states and
that may represent prognostic indicators, and drug discover, and toxicology.
Gene expression techniques also have several limitations: the output from the
analysis of a microarray experiment is usually a large data spreadsheet filled with
numbers related to the signal intensity for each gene on the chip. Further analysis is
required to identify groups of genes that are similarly regulated across the biological
samples under study. It is not a quantitative method, and so it does not perfectly
reflect the reality.
1.3.2 Protein–protein interactions
Proteins are large molecules composed of chains of amino acids that form a certain
structure, flexible, able to perform structural functions and catalysis. They play crucial
roles in living cells and in life; they perform their functions under constant motions
and have varied shapes, flexibility, and interactions with other biological molecules.
Typically, proteins interact with other proteins, metabolites, and nucleic acids within
cells. Protein–protein interactions occur when two or more proteins bind together,
often to carry out their biological function.
Interactions between proteins are important for the majority of biological func-
tions. Proteins frequently participate in the formation of protein complexes (i.e.,
group of two or more proteins) and constitute the basis of many biological processes.
A protein complex can be considered as a molecular machinery that performs most
of the biological functions (Hartwell et al., 1999). For instance, the ribosome, large
and complex molecular machine composed by hundreds of proteins, serves as the
9
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site of biological protein synthesis (i.e., translation). Protein–protein interactions
are important for virtually every process in a living cell. Information about these
interactions improves our understanding of diseases and can provide the basis for
new therapeutic approaches, since almost all the drugs are targeted to modify the
function of the specific proteins.
These kinds of interactions have been measured using a variety of assays, such as
inmuno precipitations and the yeast two-hybrid approach. These techniques have
been scaled up to measure interactions on a genome-wide level. High-throughput
techniques have also been developed to systematically identify protein complexes
using affinity purification techniques followed by mass spectrometry to sequence
proteins.
One of the great challenges for molecular biology is to reconstruct the complete
network of protein interactions within cells. The analysis of the network biology
should also permit scientists to select protein targets for therapeutic intervention
by facilitating understanding of the underlying mechanisms of action. Eventually,
protein networks may also be used to construct comprehensive dynamic models of
molecular interactions within cells, allowing scientists to quantitatively predict the
outcome of experiments.
Along with experimental approaches to detect protein interactions, computational
methods have also been developed. These methods are used to search for pairs of
proteins that have co-evolved, implying that they are likely to be interacting within
cells (de Juan et al., 2013; Ochoa et al., 2015). Even though computationally derived in-
teractions are generally not as reliable as experimentally measured ones, they provide
a more complete and accurate understanding of protein interactions in combination
with experimental data (Mosca et al., 2013).
In summary, proteins do not act alone, and they often form complexes with other
proteins to perform a specific task. Existing interactions have been studied, and we
use this information to see how those interactions evolve based on the expression of
the proteins.
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1.4 Meta-analysis
The British statitician Karl Pearson was probably the first to use meta-analytic
techniques in order to combine observations from different clinical studies in 1904
(O’Rourke, 2007). In particular, he studied the correlations between inoculations for
typhoid fever and mortality for five independent samples (Pearson, 1904). However,
the term meta-analysis used to refer to "the statistical analysis of a large collection of
analysis results from individual studies for the purpose of integrating the findings"
was not coined until 1976 by Gene Glass in his educational research (Glass, 1976). This
was followed by articles and textbooks about meta-analysis (Rosenthal, 1978; Cooper
and Rosenthal, 1980; Glass et al., 1981; John E Hunter and Jackson, 1982).
The use of meta-analysis in the medical research area began a few years later
(Stjernswärd, 1974; Chalmers et al., 1977; Chalmers, 1979) and now its use is widespread.
Figure 1.4 shows all the studies in PubMed (pub) that include the word ‘meta-analysis’
or ‘metaanalysis’ in their titles between the years 1990 and 2014. Each column rep-
resents the number of studies published within each year. The papers published
have been counted from a PubMed search with the following commands: meta-
analysis[title] OR metaanalysis[title] AND y[dp], y being each year from 1990 to 2014.
0
20
00
40
00
60
00
80
00
19
90
19
91
19
92
19
93
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
Figure 1.4: Time evolution in the number of publications on meta-analysis.
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The principal aim of a synthesis is to understand the results of any study in the
context of all the other studies. Meta-analysis is very important for the following
reasons:
• Statistical significance. The meta-analysis provides a mathematically rigorous
mechanism to test the null hypothesis.
• Clinical importance of the effect. The meta-analytic approach allows one to
compute an estimate of the effect size (e.g., in this work differentially expressed
gene (DEG)).
• Consistency of effects. Working with a large number of studies is fundamental
in determining whether or not the effect size (DEG) is consistent across studies.
1.4.1 Meta-analysis in microarrays
Today, an increasing amount of gene expression data is available in public reposi-
tories such as The Cancer Genome Atlas (tcg), GEO from NCBI (geo), and ArrayExpress
from EBI (ae). These databases contain valuable information that may lead to new
discoveries. From these repositories, one can obtain multiple datasets related to a
specific disease. But often, a single study has a small sample size and so its statistical
power is limited. Combining information coming from multiple and independent
studies linked by the same hypothesis is a practical way to increase the overall sample
size and sensitivity, reduce false positives, and provide more robust and validated
results. However, this integration is not trivial. The absence of standards for mi-
croarray experiments generates heterogeneous datasets, and a direct comparison
is not possible (Choi et al., 2003). Even though microarray experiments have been
performed in different laboratories with the same research objective, the results of
these experiments may differ from each other in many aspects, such as features of
the samples, probe sets, or the microarray platform (Shi et al., 2011). Accordingly, the
significant genes identified through different experiments may be inconsistent, even
using the same statistical analysis.
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There are several strategies to handle the combination of such large amounts
of data. Several studies directly integrate gene expression data by aligning genes
and probes and concatenating samples (Warnat et al., 2005; Xu et al., 2007, 2008),
that is, merging the data and then deriving a result (Figure 1.5b). This is, the gene
expression values are merged and then, these values are transformed into numerically
comparable measures. Meta-analysis is another way of generating more robust and
consistent statistical results by integrating multiple datasets (Figure 1.5a). Integrating
information from multiple relevant genomic studies has brought new challenges,
and microarray meta-analysis in particular has become a frequently used tool in
biomedical research in order to increase statistical power (Tseng et al., 2012).
The goal of microarray meta-analysis is to detect DEGs associated with a disease
by combining information from several studies. These DEGs might be potential
candidate markers for disease classification, diagnosis or prognosis prediction, and
help us to understand the genetic mechanisms underlying a disease. There are many
different meta-analysis methods that are used to combine information across studies
and to generate meta-analyzed p-values.
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a b
Figure 1.5: Schema of the different approaches in the integrative microarray anal-
ysis in the context of the identification of differential expressed genes (DEGs). (a)
Meta-analysis. (b) Analysis by data merging [adapted from (Taminau et al., 2014)].
Many microarray meta-analysis methods have been developed and applied in
the literature, particularly for DEG detection. Their main objective is to identify
DEGs across two or more conditions with statistical significance and/or biological
significance. According to a recent review (Tseng et al., 2012), popular methods mainly
combine three different types of statistics: p-values, effect sizes, and ranks. The truth
is that despite the availability of a large number of methods, the selection of the
meta-analysis method depends strongly on the data structure and the hypothesis to
achieve the biological goal (Chang et al., 2013). To our knowledge, there are only three
comparative studies systematically comparing multiple meta-analysis methodologies
(Hong and Breitling, 2008; Campain and Yang, 2010; Chang et al., 2013), and the
conclusions are not decisive.
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1.5 Comorbidities
Comorbidity or multimorbidity is explained as the presence of additional diseases
in relation to an index disease in one individual (Tabarés-Seisdedos et al., 2011). In
other words, comorbidity is the presence of several diseases at the same time in one
individual.
In the last few decades, epidemiological and clinical studies have been published
showing that comorbidity is a universal medical problem because patients with several
disorders are the rule rather than the exception (Valderas et al., 2009). The impact
of multimorbidity on health is significant. For instance, the research conducted by
Fortin et al. (2005) states that in a cohort of more than 700 patients, 9 out of 10 patients
had more than one chronic health problem. Along the same lines, an epidemiological
study of multimorbidity in Scotland found that almost a quarter of all patients, and
more than half of those with a common chronic disorder, have multimorbidity (Barnett
et al., 2012). The authors conducted a cross-sectional study in which the medical
records of 1,751,841 people from Scotland (more than a third of the population) were
used. These records correspond to more than 300 Scottish medical practices and were
used to analyze the distribution of multimorbidity (i.e., two disorders from a list of 40
long-term disorders) in relation to age, sex, and socioeconomic status. They found
that people with multimorbidity have a reduced quality of life, and that the prevalence
of multimorbidity increases with age and socioeconomic deprivation (particularly,
physical and mental health comorbidities).
There are two types of comorbidities: direct and inverse comorbidities. Direct co-
morbidity implies that patients with a particular disease are more likely than expected
to suffer other diseases. For example, diabetic patients have a major risk factor for
heart disease and hypertension (Bell, 2004), patients infected with hepatitis C have a
major risk of liver cancer (El-Zayadi, 2009), and women infected with human papillo-
mavirus are more likely to develop cervical cancer (Hernández-Avila et al., 1997). In
contrast, inverse comorbidity is characterized by a lower than expected probability
of certain diseases occurring in individuals diagnosed with other health conditions
(Tabarés-seisdedos and Rubenstein, 2013). For example, studies on cancer risk among
patients suffering Parkinson’s disease show significantly reduced cancer risk ratios
compared to patients without Parkinson’s disease (Bajaj et al., 2010).
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Many studies analyzing comorbidities between different complex disorders have
been published in the last decades. For instance, (Catalá-López et al., 2014a) carried
out a meta-analysis of cancer incidence in 577,013 patients from 50 observational
studies. They assess the co-occurrence of cancer in patients with CNS disorders,
including Alzheimer’s disease (AD), amyotrophic lateral sclerosis, autism spectrum
disorders, Down’s syndrome, Huntington’s disease, multiple sclerosis, Parkinson’s
disease, and schizophrenia. Figure 1.6 sums up graphically the comorbidities they
have found between the diseases under study. It shows the relationships among
several kinds of cancer and CNS disorders (Parkinson’s disease (PD), multiple sclerosis
(MS), schizophrenia (SCZ), Down’s syndrome (DS), Huntington’s disease (HD), and
Alzheimer’s disease AD)) comorbidities. Red lines represent direct comorbidity cases
and green lines represent inverse comorbidity cases.
PD
MS
SCZ
DS
HD
AD
Overall
CANCERCNS
Lung
Prostate
Colorectal
Melanoma
Brain
Breast
Lymphoma
Testicular
Leukaemia
Malignancies of the
haemopoietic &
Lymphoid Tissues
Neurodegenerative
Disorders
p-value < 0.1
p-value < 0.05
Figure 1.6: Relationships among several kinds of cancer and CNS disorders comor-
bidities (Figure provided by Dr. Tabarés-Seisdedos). Dotted line represent p-values
lower than 0.1, and continuous lines p-values lower than 0.05.
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They observe that the presence of any CNS disorder is associated with a reduced
co-occurrence of cancer. In particular, patients with Alzheimer’s disease, Parkin-
son’s disease, multiple sclerosis, and Huntington’s disease have a lower overall co-
occurrence of overall cancer (Catalá-López et al., 2014a). By contrast, they observe
that patients with Down’s syndrome have a higher overall co-occurrence of cancer.
Hasle et al. (2000) also found that patients with Down’s syndrome have a strong risk of
increased co-occurrence of cancer, specifically gastrointestinal and testicular cancers
and leukemia.
For both direct and inverse comorbidities, the underlying biological mechanisms
are not well described. There are different factors that might account for comorbidity:
drug treatments and derived side-effects, clinical factors, an unhealthy lifestyle, the
environment, the low incidence of screening, poor access to healthcare, differences in
socioeconomic status, and genetic susceptibility (Tabarés-Seisdedos et al., 2011).
1.5.1 Inverse comorbidities
Inverse comorbidity or inverse multimorbidity is characterized by a lower than
expected probability of certain diseases occurring in individuals with other health
problems (Tabarés-Seisdedos and Rubenstein, 2009). In this work, we focus on this
kind of medical condition because it provides a new and potentially better scenario
for the study of the biological mechanisms that are behind many complex disorders.
Most of the diseases associated with inverse cancer comorbidity are neurological
disorders or central nervous system (CNS) disorders (Tabarés-Seisdedos and Ruben-
stein, 2009), and they have been previously established by a series of observational
studies (Hasle et al., 2000; Catts et al., 2008; Bajaj et al., 2010). This relationship in
people with certain CNS disorders is an invaluable opportunity to gain insight into
the pathogenesis of these complex diseases, and understanding why certain individu-
als with CNS disorders are protected against different kinds of cancer could help in
developing new treatments, by drug repurposing (Tabarés-seisdedos and Rubenstein,
2013).
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Figure 1.7: Forest plot of (a) the risk of cancer in people with Alzheimer’s disease,
and (b) the risk of Alzheimer’s disease in people with cancer (Catalá-López et al.,
2014b) (Figure provided by Dr. Catalá-López).
Several research groups worldwide have published studies related to this condition.
Many studies go in the direction of an existing inverse comorbidity between cancer and
Alzheimer’s disease (Behrens et al., 2009; Driver et al., 2012; Thinnes, 2012; Musicco
et al., 2013; Ou et al., 2013; Ma et al., 2014; Romero et al., 2014; Driver et al., 2015).
For instance, Driver et al. (2012) followed 1,278 participants with and without a
history of cancer for 10 years, and 221 cases of Alzheimer’s disease were detected.
They concluded that patients with a history of cancer have a lower risk of Alzheimer’s
disease, and patients with Alzheimer’s disease have a lower risk of subsequent cancer.
A recent study carried out by Catalá-López et al. (2014b) validates and quantifies these
epidemiological findings. The authors searched all observational noninterventional
studies published up to July 2013 reporting valid measures of the comorbidity-related
risk of Alzheimer’s disease and cancer. The forest plot (Figure 1.7) shows the risk of
cancer in people with Alzheimer’s disease and the risk of Alzheimer’s disease in people
with cancer. These significant findings are in line with those of other studies: there is
a mutual protection between Alzheimer’s disease and cancer.
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Inverse comorbidity between Parkinson’s disease and cancer have also been pub-
lished (Bajaj et al., 2010; Catalá-López et al., 2014a). In particular, Catalá-López et al.
(2014a) observed that patients with Parkinson’s disease have a significantly reduced
co-occurrence of cancer in general and particularly of lung, prostate, and colorectal
cancer.
The inverse medical condition found between schizophrenia and cancer is not so
clear. Many studies state that a mutual protection between cancer and schizophrenia
exists but that it depends on the age (Lin et al., 2013b,a). Cancer risks in patients with
schizophrenia are lower for cancers that are more likely to develop at older ages in the
general population (e.g., stomach, pancreatic, and prostate cancer), and cancer risks
are higher for cancers that have a younger ager of onset (e.g., breast or uterine corpus
cancer).
1.6 Motivation
The data generated in Life Sciences are huge and mining such data is twice over.
On one hand, data in Life Sciences are heterogeneous. On the other hand, such data
are produced massively and repositories are becoming large and large. Data mining
and in special, machine learning, is concerned with the development of efficient
algorithms and mathematical models to find patterns and statistical dependencies in
huge volumes of data. In particular, machine learning methods in Systems Biology are
used to explore molecular networks to automatically discover and model properties,
interactions, and behavior in biological systems.
Taking advantage of the first available biological data associated with complex
disorders is an interesting way to develop different computational approaches to
study the molecular bases of the inverse comorbidity between different disorders, to
analyze the stability of the protein–protein interaction networks in different scenarios,
and to classify proteins that might be essential in the disorders under study.
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The goal of the thesis is to study the biological mechanisms behind the inverse
comorbidity between certain kinds of cancer and CNS disorders developing compu-
tational approaches based on machine learning and pattern recognition techniques.
Understanding why people with certain CNS disorders are protected against some
forms of cancer might be the key to finding novel treatments for both types of condi-
tions.
Figure 1.8: Scheme of the thesis.
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1.7 Objectives
The main goal is to develop novel computational approaches in order to study
diverse perspectives associated with the inverse comorbidity between some kinds
of cancer and CNS disorders using gene expression data, and combining them with
protein–protein interaction network.
The objectives in this thesis are the following:
(a) Study for the first time the molecular processes in common between different
types of cancer and CNS disorders using transcriptomic data.
• Implement a computational approach that can be used to conduct tran-
scriptomic meta-analyses between different complex disorders.
(b) Analyze for the first time differences in network stability between cancer and
CNS disorders.
• Develop a computational approach inspired on Simulated Annealing to
study the stability of protein–protein interaction networks using gene
expression data obtained by studying cancer and neurological disorders.
(c) Elaborate a classification strategy to distinguish proteins related to cancer from
proteins related to CNS disorders.
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1.8 Contributions
1.8.1 Publications in journals related with this thesis
1. Ibáñez, K., Boullosa, C., Tabarés-Seisdedos, R., Baudot, A., and Valencia, A.
Molecular Evidence for the Inverse Comorbidity between Central Nervous Sys-
tem Disorders and Cancers Detected by Transcriptomic Meta-analyses. PLoS
Genet., 10(2):e1004173, 2014. ISSN 1553-7404. doi: 10.1371/journal.pgen.
1004173
In this work we present a data mining approach to compute transcriptomic
meta-analyses of different complex disorders. In particular, we study three
CNS disorders (Alzheimer’s disease, Parkinson’s disease, and schizophrenia) and
three cancer types (lung, prostate, and colorectal) previously described with
inverse comorbidities. A significant overlap is observed between the genes up-
regulated in CNS disorders and down-regulated in cancers, as well as between
the genes down-regulated in CNS disorders and up-regulated in cancers. We also
observe expression deregulations in opposite directions at the level of pathways.
Our analysis points to specific genes and pathways, the up-regulation of which
could increase the incidence of CNS disorders and simultaneously lower the
risk of developing cancer, while the down-regulation of another set of genes
and pathways could contribute to a decrease in the incidence of CNS disorders
while increasing the cancer risk. These results suggest that the presenting
methodology can be used for other diseases to study comorbidities or other
biological hypothesis, and it also might be used with other kind of biological
data, different from transcriptomic nature.
The complete description of this work can be found in Chapter 2.
2. Ibáñez, K., Guijarro, M., Pajares, G., and Valencia, A. A computational approach
inspired by simulated annealing to study the stability of protein interaction
networks in cancer and neurological disorders. Data Min. Knowl. Discov., 2015.
ISSN 1384-5810. doi: 10.1007/s10618-015-0410-5
In this work we present a novel approach to analyze the stability of protein
interaction networks in cancer and CNV disorders. Specifically, the methodology
we propose is inspired on the deterministic Simulated Annealing algorithm.
Adjusted energy values are used to compare the network stability in disease
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and control states in ovarian, colon, liver and kidney cancers, and Alzheimer’s
disease and schizophrenia. Our results show that cancer networks are less
stable than the Alzheimer’s disease ones. These results can be interpreted in
terms of our previous observations on cancer and Alzheimer’s disease inverse
comorbidity, i.e. Alzheimer’s disease patients have lower than expected risk to
suffer cancer.
The complete description of this work can be found in Chapter 3.
1.8.2 Communications in conferences
The following works propose diverse computational approaches and data min-
ing based techniques to analyze different aspects regarding the inverse comorbidity
between some types of cancer and CNS or neurological disorders. Most of them
constitute preliminary versions of the works published afterwards or submitted to
international journals.
1. Ibáñez K., Guijarro M., Pajares G., Valencia A.
Stability of Cancer and Alzheimer’s Interaction Networks, a Simulated Annealing
based Approach
Conference on Network Biology Community in conjunction with International
Society of Computational Biology (ISCB), July 11th 2014, Boston, USA.
The communication in this conference described a preliminary version of the
work described in Chapter 3.
2. Ibáñez K., Boullosa C., Tabarés-Seisdedos R., Baudot A., Valencia A.
Inverse Comorbidity between Central Nervous System Disorders and Cancers
interpreted by Transcriptomic Meta-analyses
XI Spanish Symposium on Bioinformatics, September 21-24th 2014, Seville,
Spain
The oral communication in this conference presented the final results of the
work described in Chapter 2 and in the already published work (Ibáñez et al.,
2014).
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1.8.3 Other publications
1. Kamieniak, M. M., Rico, D., Milne, R. L., Muñoz Repeto, I., Ibáñez, K., Grillo,
M. A., Domingo, S., Borrego, S., Cazorla, A., García-Bueno, J. M., Hernando, S.,
García-Donas, J., Hernández-Agudo, E., Y Cajal, T. R., Robles-Díaz, L., Márquez-
Rodas, I., Cusidó, M., Sáez, R., Lacambra-Calvet, C., Osorio, A., Urioste, M.,
Cigudosa, J. C., Paz-Ares, L., Palacios, J., Benítez, J., and García, M. J. Deletion at
6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer
patients. Mol. Oncol., 2014. ISSN 1878-0261. doi: 10.1016/j.molonc.2014.09.010
In this work a validation of array CGH is done with external data by means of
an adaptation and application of a computational algorithm based on previous
strategies. Here predictors of clinical outcome for advanced high-grade serous
ovarian carcinoma are studied. The research work consists in analyze 42 ovarian
carcinoma samples, evaluating the utility of DNA copy number alterations. In
this manner, the loss at 6q24.2-26 is significantly associated with the group of
samples of longer survival. This prognostic value is validated in two independent
series, one consisting of 36 samples analyzed by fluorescent in situ hybridization
and another comprised by 411 ovarian carcinoma samples from the Cancer
Genome Atlas (TCGA) repository. This validation with external data corresponds
to the computational analysis in the study, a combination of the adaptation and
application of the R DNAcopy and CGHcall algorithms.
2. Pons, T., Paramonov, I., Boullosa, C., Ibáñez, K., Rojas, A. M., and Valencia,
A. A common structural scaffold in CTD phosphatases that supports distinct
catalytic mechanisms. Proteins, 82(1):103–18, 2014. ISSN 1097-0134. doi:
10.1002/prot.24376
3. Frenkel-Morgenstern, M., Gorohovski, A., Lacroix, V., Rogers, M., Ibanez, K.,
Boullosa, C., Andres Leon, E., Ben-Hur, A., and Valencia, A. ChiTaRS: a database
of human, mouse and fruit fly chimeric transcripts and RNA-sequencing data.
Nucleic Acids Res., 41(D1):D142–D151, 2012. ISSN 0305-1048. doi: 10.1093/nar/
gks1041
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1.8.4 Other communications
1. Ibáñez K., Silla-Castro JC., Martin-Arenas R., Barroso E., Del Pozo A.
Toward the Characterization of Patterns in Dravet Syndrome combining Next
Generation Sequencing, Clinical Data and Machine Learning techniques
23rd International Conference on Intelligent Systems for Molecular Biology, July
10-14 2015 Dublin, Ireland
2. Silla-Castro JC., Ibáñez K., Lapunzina P., Del Pozo A.
RAMBO: Really Accessible Management of Bioinformatics Outcome in massive
parallel sequencing for clinical studies
23rd International Conference on Intelligent Systems for Molecular Biology, July
10-14 2015 Dublin, Ireland
3. Del Pozo A., Ibáñez K., Silla-Castro JC., Lapunzina P.
A non-invasive bioinformatic method for analysis of fetal aneuploidy in mater-
nal blood by Next Generation Sequencing
23rd International Conference on Intelligent Systems for Molecular Biology, July
10-14 2015 Dublin, Ireland
4. Ibáñez K., Silla-Castro JC., Lapunzina P., Del Pozo A.
LACONv, Método Para la Detección de Variación en número de copia usando
la cobertura de las lecturas de ADN en paneles personalizados de genes en
secuenciación masiva
XXVIII Congreso Nacional de Genética Humana - AEGH, May 13-15 2015 Palma
de Mallorca, Spain
5. Del Pozo A., Ibáñez K., Silla-Castro JC., F.Montaño VE., Campos-Barros A.,
Moreno JC., Heath KE., González-Casado I., Aguado B., Luna A., Nevado J.,
Vallespín E., Lapunzina P.
Secuenciación Masiva en la Práctica Clínica: Ajuste de la técnica en una cohorte
de pacientes con patología endocrina
XXVIII Congreso Nacional de Genética Humana - AEGH, May 13-15 2015 Palma
de Mallorca, Spain
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6. Del Pozo A., Silla-Castro JC., Ibáñez K., Lapunzina P.
Estudio de los predictores de patogenicidad in-silico para guiar el diagnóstico
en NGS
XXVIII Congreso Nacional de Genética Humana - AEGH, May 13-15 2015 Palma
de Mallorca, Spain
7. Prieto-Arribas D., Del Pozo A., Ibáñez K., Silla-Castro JC., Vallespín E., Fernández-
Montaño VF., Mori AM., Mansilla E., Rodríguez R., Nevado J., de Torres ML.,
Lapunzina P., García-Santiago F.
Método no invasivo para el análisis de aneuploidías fetales en sangre materna
mediante NGS
XXVIII Congreso Nacional de Genética Humana - AEGH, May 13-15 2015 Palma
de Mallorca, Spain
8. Lucero A.M., Colicheo A., Cambiasso O., Santos-Simarro F., Fernández L., Mena
R., Montaño V.F., Ibáñez K., García-Miñaúr S., Nevado J., Silla-Castro JC., Lapun-
zina P., del Pozo A., Vallespín E.
Diagnóstico del síndrome de Marfan mediante el estudio del gen FBN1 por NGS
XXVIII Congreso Nacional de Genética Humana - AEGH, May 13-15 2015 Palma
de Mallorca, Spain
9. Montaño V.F., Fernández L., Ibáñez K., Prior C., Arribas A., Gutiérrez-Larraya
F., Oliver-Ruiz JM., García-Guereta L., Deiros L., Martín-Arenas R., Rodríguez-
Laguna L., Silla-Castro JC., Lapunzina P., del Pozo A., Vallespín E.
Panel personalizado de NGS CardioMass_V1.0 en la rutina clínica diagnóstica
de cardiopatías
XXVIII Congreso Nacional de Genética Humana - AEGH, May 13-15 2015 Palma
de Mallorca, Spain
10. Martín-Arenas R., Fernández L, Ibáñez K., Malpartida SG., Alfonso-Núñez M.,
International Consortium, Guillén E., Lapunzina P., Barroso E.
Identificación de nuevas mutaciones en el gen PCDH19 en pacientes con epilep-
sia limitada a mujeres con retraso mental asociado (EFMR)
XXVIII Congreso Nacional de Genética Humana - AEGH, May 13-15 2015 Palma
de Mallorca, Spain
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11. Ibáñez K., Silla-Castro JC., Lapunzina P., Del Pozo A.
Detection of Large Copy Number Variation Algorithm using Read-Depth of
Coverage in Fitted Panels of Genes
XI Spanish Symposium on Bioinformatics, September 21-24th 2014, Seville,
Spain
12. Del Pozo A., Silla-Castro JC., Ibáñez K., Campos-Barro A., Moreno JC., Heath K.,
Nevado J., Fdez-Montaño ME., Vallespín E., Lapunzina P.
Next Generation Sequencing in Clinical Practice: Challenges and Promises in a
Cohort of Endocrine Patients
XI Spanish Symposium on Bioinformatics, September 21-24th 2014, Seville,
Spain
1.9 Thesis layout
This thesis is divided in three blocks. Chapter 2 presents a computational ap-
proach capable of identifying candidate genes potentially associated with the inverse
comorbidity through a transcriptomic meta-analysis. The identification of inversely
deregulated genes and pathways in complex diseases that have been previously de-
scribed as inversely comorbid provides, to our knowledge, the first systematic insights
into the possible molecular basis of these associations.
Proteins are not islands, and so, they are somehow connected with other proteins.
In order to understand the mechanism of the entire system we must analyze the
interactions between proteins. In chapter 3 we propose a model that studies the
stability of protein–protein interaction networks in cancer and neurological or CNS
disorders.
Following the model presented in chapter 3, a pattern recognition is exposed
in chapter 4 for protein recognition depending on many structural properties. We
propose the definition of features that are capable to identify proteins that are related
to some types of cancer and to neurological disorders.
Chapter 5 describes the general conclusions of the work as a whole and sums up
the main conclusions of each of the three works that comprise this thesis.
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2 Towards the molecular basis of
comorbidity between cancer and CNS
disorders
2.1 Summary
We present here a novel data mining approach in order to compute transcriptomic
meta-analyses in complex disorders, particularly, between some types of cancer and
Central Nervous System (CNS) disorders. A significant overlap is observed between the
genes upregulated in CNS disorders and downregulated in cancers, as well as between
the genes downregulated in CNS disorders and upregulated in cancers. These genes
upregulated and downregulated in each disease tissue correspond to a significant
major or minor expression between their corresponding healthy tissue, respectively.
Moreover, the patients and the tissues are different for cancer and CNS diseases. When
these genes are analyzed at the level of pathways, it is observed that they are somehow
clustered in pathways with a clear biological significance which goes in the direction
of the inverse comorbidity. Our analysis points to specific genes and pathways, the up-
regulation of which could increase the incidence of CNS disorders and simultaneously
lower the risk of developing cancer, while the down-regulation of another set of genes
and pathways could contribute to a decrease in the incidence of CNS disorders while
increasing the cancer risk. These results have been published in (Ibáñez et al., 2014).
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2.2 Introduction
2.2.1 Inverse comorbidity
Epidemiological evidences point to a lower-than-expected probability of develop-
ing some types of cancer in certain CNS disorders (Behrens et al., 2009; Devine et al.,
2011; Tabarés-Seisdedos et al., 2011; Behrens et al., 2012; Catalá-López et al., 2013;
Tabarés-seisdedos and Rubenstein, 2013; Catalá-López et al., 2014b).
Our current understanding of such inverse comorbidities suggests that this phe-
nomenon is influenced by environmental factors, drug treatments and other aspects
related with disease diagnosis. Genetics can additionally contribute to the inverse
comorbidity between complex diseases [for review, see (Behrens et al., 2009; Devine
et al., 2011; Catalá-López et al., 2013; Tabarés-seisdedos and Rubenstein, 2013)]. This
intriguing association represents an invaluable opportunity to understand why certain
individuals are protected against different types of cancer and to discover if there are
molecular mechanisms that underlie this protection. In particular, we propose here
the deregulation in opposite directions of a common set of genes and pathways as a
molecular mechanism directly related with inverse comorbidity. Using transcriptional
data, we tested whether there is a significant overlap between genes that are up-
regulated in cancer and down-regulated in CNS disorders and the other way around
(Figure 2.1).
Figure 2.1: Idea.
In particular, based on the study of (Tabarés-Seisdedos et al., 2011), we have
focused our study on schizophrenia (SCZ), Alzheimer’s (AD) and Parkinson’s diseases
(PD), and colorectal (CRC), lung (LC) and prostate (PC) cancers (Table 2.1), where the
medical observations of inverse comorbidity are particularly strong.
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Increased co-occurrence
of cancer
Decreased co-occurrence
of cancer
Parkinson’s disease Malignant melanoma,
and skin, breast and thy-
roid cancers
Smoking-related can-
cers (especially lung, col-
orectal and bladder can-
cer), and non-smoking-
related cancers (espe-
cially prostate cancer)
Schizophrenia Breast cancer Lung, colorectal and
prostate cancers
Alzheimer’s disease None known All types of cancer
Down’s syndrome Acute leukaemias, testicu-
lar cancer, some gastroin-
testinal cancers, extrago-
nadal germ-cell tumours,
and retinoblastoma
Solid tumours (eg, neu-
roblastoma, medulloblas-
toma and other embry-
onal tumours of child-
hood, and breast and skin
cancer in adults)
Diabetes Pancreatic, liver, colorec-
tal and bladder cancers,
and non-Hodgkin lym-
phoma (type 2 diabetes)
Lung cancer, Hodgkin’s
lymphoma (type 1 di-
abetes), and prostate
cancer (type 1 and 2 di-
abetes)
Anorexia nervosa Non-Hodgkin lymphoma Breast cancer
Allergy-related diseases Oesophageal and colorec-
tal cancer, myeloma and
prostate cancer
Bladder cancer, Hodgkin’s
and non-Hodgkin lym-
phoma, and breast and
pancreatic cancers
Multiple sclerosis Brain tumours Lung cancer
Table 2.1: Summary of published findings about increased and decreased co-
occurence of cancer in people with other complex diseases (Tabarés-Seisdedos
et al., 2011).
2.2.2 Meta-analysis for DEG detection
We have performed integrative meta-analyses of collections of gene expression
data, publically available for AD, PD and SCZ in CNS disorders, and LC, CRC and
PC in cancer. Our objective is to detect differentially expressed genes (DEGs) in
expression microarrays of samples labeled with two conditions (e.g., cases versus
controls), in a collection of studies with different number of samples. Microarray
meta-analysis is usually applied combining multiple studies of related conditions to
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better detect these DEGs, increasing the statistical power, reducing false positives and,
providing more robust and validated conclusions. For this problem, two major types
of statistical procedures have been more frequently used in the literature: combining
effect sizes and combining p-values (Song and Tseng, 2014). From a theoretical
point of view, there is no single method which performs uniformly better than the
others in all datasets for various biological objectives (Littell and Folks, 1971). From a
practical point of view, several studies have been published comparing and statistically
characterizing different meta-analysis methods with no deciding outcome (Hong and
Breitling, 2008; Campain and Yang, 2010; Chang et al., 2013).
In this part of the work, we used the combining effect sizes strategy. The Fixed
Effects Model (FEM) and the Random Effects Model (REM) are the most popular
methods (Cooper et al., 2009). This approach has many advantages to be applied to
microarray data: 1) It provides a standardized index (the measure of gene expression
levels is not interchangeable). 2) It can be easily combine different results by integrat-
ing microarray data. 3) It is superior to other meta-analytic approaches, due to the
power of handle the variability between studies (Choi et al., 2003). FEM and REM are
usually more powerful to directly synthesize information of the effect size estimates,
compared to p-value combination methods (Song and Tseng, 2014). Indeed, they are
particularly applicable to samples with two conditions (cases versus controls) when
the effect sizes can be defined and thus, combined.
Accordingly, we have made use of FEM and REM meta-analysis statistical proce-
dures for DEGs detection, identifying genes differentially expressed with statistical
and biological significance.
2.3 Material
We propose a strategy to test whether gene expression is involved in the presence
of inverse comorbidity between different kinds of cancer and CNS disorders. For
such aim, we have developed a pipeline which discovers relationships between gene
expression data from different kinds of human disorders have been retrieved.
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2.3.1 Gene expression data
Gene expression raw data (CEL files) have been downloaded from NCBI GEO
omnibus (geo), EBI ArrayExpress (ae) and Stanley Medical Research Institute Online
Genomics Database (smr) for CRC, LC and PC in cancers, AD, PD and SZC in neurolog-
ical disorders, and for asthma, HIV, malaria, dystrophy, sarcoidosis in control diseases.
Details of the selected gene expression studies are listed in Table 2.2.
For each disease, experimental gene expression studies have been filtered to select
only the ones profiling at least 9 samples for disease and control cases (statistical rea-
sons), with Affymetrix arrays (GeneChip® Human Genome U133 Plus 2.0, GeneChip®
Human Genome U133A and GeneChip® Human Genome U133A 2.0 containing
23,945, 14,538 and 14,538 genes, respectively). For CNS disorders, only studies that
measure gene expression in brain tissues have been selected. For cancers, only gene
expression studies carried out in the LC, CRC and PC tumor tissues have been consid-
ered (i.e., blood is not considered). Even though brain tissue is not often available, it
has been seen that gene expression in blood is poorly preserved comparing to tissue
(Cai et al., 2010).
Table 2.2: Gene expression datasets.
Tissue Platform
Sample
Size
Source
Alzheimer’s disease
Entorhinal Cortex HG-U133Plus2 23 GSE5281
Hippocampus HG-U133Plus2 23 GSE5281
Medial Temp. Gyrus HG-U133Plus2 28 GSE5281
Posterior Singulate HG-U133Plus2 22 GSE5281
Primary Visual Cortex HG-U133Plus2 31 GSE5281
Superior Frontal Gyrus HG-U133Plus2 34 GSE5281
Hippocampus HG-U133Plus2 24 GSE1297
Parkinson’s disease
Postmortem substantia
nigra
HG-U133Plus2 25 GSE7621
Postmortem medial, lateral
and frontal
HG-U133A 45 GSE8397
Substantia nigra HG-U133A 29 GSE20292
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Table 2.2 – Gene Expression datasets
Tissue Platform
Sample
Size
Source
Schizophrenia
Postmortem cerebellum HG-U133Plus2 28 GSE4036
Postmortem frontalBA46
cortice
HG-U133Plus2 55 Dobrin
Postmortem hippocampus
(CA1)
HG-U133Plus2 41 Laeng
Postmortem thalamus (MD) HG-U133Plus2 26 Kemether
Postmortem frontalBA46
cortice
HG-U133A 67 AltarA
Postmortem frontalBA46
cortice
HG-U133A 50 AltarC
Postmortem frontalBA46
cortice
HG-U133A 67 Bahn
Postmortem frontalBA46
cortice
HG-U133A 69 Kato
Colorectal cancer
Colon macro- and micro-
dissected
HG-U133Plus2 105 GSE20916
Colon tissue HG-U133Plus2 64 GSE8671
Colon tissue HG-U133Plus2 81 GSE9348
Colon tissue HG-U133Plus2 33
GSE4183
GSE7307 (GSM175905)
GSE2109
Lung cancer
Lung tissue HG-U133Plus2 178
GSE3526
GSE19188
Lung tissue HG-U133A 54 GSE7670
Lung tissue HG-U133A 107 GSE10072
Prostate cancer
Prostate tissue HG-U133Plus2 122 GSE17951
Prostate tissue HG-U133A 57 E-TABM-26
Prostate tissue HG-U133A2 89 GSE6956
Malaria
Peripheral blood mononu-
clear cells
HG-U133A 36 GSE5418
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Table 2.2 – Gene Expression datasets
Tissue Platform
Sample
Size
Source
Muscular Dystrophy
Quadriceps muscle HG-U133A 37 GSE6011
Quadriceps and biceps mus-
cle
HG-U133A 20 GSE11681
Pulmonar Sarcoidosis
Lung tissue HG-U133Plus2 12 GSE16538
Asthma
Circulating CD4+ and CD8+
T-cells
HG-U133Plus2 40 GSE31773
Alveolar macrophage sam-
ples from bronchoalveolar
lavages
HG-U133A 10 GSE22528
HIV
Lymph node tissue HG-U133Plus2 34 GSE16363
Centrum semiovale(deep
white matter)
HG-U133Plus2 25 GSE28160
2.4 Methods
We have developed a methodology that follows the steps represented in Figure 2.2.
The first stage corresponds to select the most suitable available studies and to retrieve
the corresponding gene expression raw data with the filters previously mentioned
at section 2.3 (Step 1). Then, gene expression data is preprocessed (Step 2), and a
meta-analysis is done (Step 3). As result, for each disease, a consensus gene set of
DEGs is obtained. From this point two different aspects are done. Concurrently, a
gene-based analysis is done using the Fisher’s exact test to compute whether DEGs of
a particular disease are enriched in DEGs from other different diseases (Step 4), and a
pathway-based analysis is also done (Step 5).
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Suitable microarray
datasets identification
(Step 1)
Gene expression
normalization
(Step 2)
Gene expression
meta-analysis
(Step 3)
DEGs analysis
Fisher's exact test
(Step 4)
GSEA analysis
(Step 5)
Figure 2.2: Workflow with the steps of the proposed methodology.
A literate programming and dynamic report with a thorough description of our
analysis workflow is accessible [see the supplementary material (Ibáñez et al., 2014)].
The completing code contains a step-by-step description of the analysis, and the code
can also be executed directly into R. It hence provides the detailed explanations of the
tools and the parameters, and allows the complete reproduction of our results.
2.4.1 Microarray data selection (Step 1)
The dataset selection is fundamental. The data quality is one of the most important
obstacle in order to achieve a successful meta-analysis (Eysenck, 1994). The use of
a poor quality data set in the combination of a large number of studies can greatly
attenuate the information contained (e.g., more noise), losing the statistical power
or even putting out of true the final biological conclusions (Kang et al., 2012). Up to
this point, the amount of studies which combine relevant and homogeneous data
in genomic meta-analysis is increasing, but the data quality control is ignored and
the inclusion/exclusion criteria usually depends on experts’ opinion or on a naïve
threshold by sample size or microarray platform.
Kang et al. (2012) propose a methodology called MetaQC, with objective quality
control (QC) and inclusion/exclusion criteria for genomic meta-analysis. They pro-
pose several quantitative quality control measures, particularly covering accuracy and
consistency of DEGs detection. The robustness and effectiveness of the methodology
is demonstrated [see (Kang et al., 2012)], and it has been already used in other studies
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(Wang et al., 2012; Rung and Brazma, 2013; Manczinger and Kemény, 2013; Chang
et al., 2013; Chikina and Sealfon, 2014; Song and Tseng, 2014; Kim et al., 2014).
After having selected gene expression datasets containing at least 9 samples for dis-
ease and control cases for statistical reasons with one of the two Affymetrix platforms
(see Section 2.3.1), MetaQC R package (Kang et al., 2012) has been used in order to
assess the inclusion/exclusion criteria, taking advantage of preprocessed gene expres-
sion data. The fact of include an additional informative study to the meta-analysis can
provide increased statistical power to detect more DEGs, but adding a lower quality
score can deteriorate the performance.
2.4.2 Microarray gene expression normalization (Step 2)
The preprocessing or normalization step is essential to avoid using bad data,
distinguish noise and the actual biological data, and to be able to compare data from
multiple arrays. The collected microarray data from the different experimental studies
are normalized. The raw data consists in an image file with fluorescence intensity
values stored. These intensities correspond to levels of hybridization produced by the
microarray platform. The preprocessing or normalization means to convert the raw
data into useful biological data. Thus, image data should be translate into intensity
values, and bias should be also removed.
Accordingly, the raw data are normalized with frozen Robust Multiarray Analysis
(fRMA) (McCall et al., 2012) from the R Affy package (Gautier et al., 2004), which
removes certain batch effects by down-weighting probes that have high between-
batch residual variance [see supplementary material (Ibáñez et al., 2014) for the code].
2.4.3 Microarray gene expression meta-analyses (Step 3)
As it has been previously described in Section 1.4, the meta-analytic techniques
are useful to combine observations from large amount of experimental studies for
the purpose of integrating the findings. Even though microarray experiments have
been performed in different laboratories with the same research objective, the results
of these experiments may differ from each other in many aspects, such as features
of the samples, probe sets, or the microarray platform (Shi et al., 2011). Accordingly,
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a meta-analytic strategy is essential to identify consistent significant genes through
different experiments.
There are several strategies to handle the combination of large amounts of data
(such as represented in Table 2.2). Particularly, the goal of microarray meta-analysis
is to detect DEGs associated with a disease by combining data from several studies.
Rhodes et al. (2002) presented an inter-study validation of microarray meta-analysis
and the most developed meta-analytic method is combining effect sizes. According
Cohen’s (1988) definition, the effect size is the magnitude, or size, of an effect. In
this case the change of gene expression in each disease is expressed as ’effect size’, a
standardized index measuring the magnitude of a treatment or covariate effect. An
effect size based approach has beneficial features to be applied to microarray data: It
provides a standardized index, and it is superior to other meta-analytic methodologies
because it has the ability to manage the variability between all the gene expression
datasets that are combined.
Hence, we propose a meta-analysis strategy based on the effect sizes because
it allows the identification of consistent genes up- and down-regulated in all the
experimental studies. The effect sizes are combined to obtain the estimate of the
overall mean. Accordingly, the combination of effect sizes gives information about the
magnitude and direction (up- or down-) of the gene expression. The principal idea is
to compute DEGs for each study, and then work with them to assess the consistency of
the effect across studies, computing then a summary effect. This summary effect is the
mean of the effect sizes, assigning more weight to the more precise studies (Borenstein
et al., 2011). In others words, a DEG is differentially expressed if it is differentially
expressed in all the studies, generating a study-invariant list, removing experimental
or technical inconsistencies between the different studies (Li and Tseng, 2011).
In order to assess the differential expression of a gene, a standardized mean differ-
ence is used as an effect size index (Equation 2.1) (Hedges and Olkin, 1985).
d = X¯d − X¯n
Sp
(2.1)
where X¯d and X¯n represent the means of the disease (d) and normal (n) groups
respectively, and Sp indicates an estimate of the pooled standard deviation. Datasets
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with n samples (both cases and controls), the unbiased estimate is obtained as d ′ =
d −3d/(4(n−2)−1), indicating the correction for sample size bias. The estimated
variance of the unbiased effect size is obtained as σ2d = (n−1d +n−1n )+d 2(2(nd +nn))−1,
where nd and nn are the sample sizes of each group (disease, normal) and d is the
unbiased effect size (Hedges and Olkin, 1985). This indicates the precision of the
measure each dataset or study provides.
Letµ be the overall mean of the expression of a gene in all the datasets (for instance,
in the AD), and Yi the observed effect size for each independent dataset. The general
model is given as:
Yi = θi +²i , ²i ∼N (0, s2i )
θi =µ+δi , δi ∼N (0,τ2)
(2.2)
where τ2 represents the between-study variance (i.e., the variability between the
studies) and s2 describes the within-study variance (i.e., the sampling error condi-
tioned on the i th study). Here Yi and s2i are given by d and σ
2
d described previously,
and µ is the average measure of the differential expression of a gene across all the
datasets.
There are two different approaches when effect sizes are computed:
• Fixed Effect Model (FEM)
FEM model assumes that all the studies in the meta-analysis share a true effect
size (fixed effect) and that all the differences in observed effects are due to
sampling error (Borenstein et al., 2011), because each study uses a different set
of participants. In other words, the factors that could vary the effect size are the
same in all the studies within the meta-analysis and so, the effect size is just the
same in all the studies. It also follows that the observed effect size might vary
among studies due to the random error inherent in each study. In this manner,
τ2 = 0 and consequently, Yi ∼N (µ, s2i ) (Choi et al., 2003).
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Figure 2.3: Schematic of the FEM model [adapted from (Borenstein et al., 2010)].
The FEM model is depicted in Figure 2.3 with an example of a disease with two
gene expression datasets (V1 and V2) that share a common (true) effect size (µ).
For each study, the true score is represented by a filled circle. The circle for each
study falls at the common µ, since all the studies are assumed to share the same
effect size. The filled square in each study represents the observed mean, which
differs from the true mean because an estimation error. The observed effect size
for study i is:
Yi =µ+²i (2.3)
where ²i represents the difference between the common mean and the observed
mean for the study i . In this way, following the definition of FEM, there is only
one way of variation: the estimation error (²i ).
• Random Effect Model (REM)
REM model by contrast, assumes that the true effect could vary among the
studies. For instance, the effect size might be lower or higher in studies in which
patients are older than the others. It is very common that studies within the
meta-analysis have been implemented or developed in different conditions or
they differ in the collection of patients, among other reasons. Thus, in REM it is
assumed that there might be different effect sizes underlying different studies
(Borenstein et al., 2011). In this manner, the effect size is computed from a
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distribution with a study-specific mean θi and variance s2i . Indeed, each θi is
assumed to be draw from some superpopulation with the overall mean µ and
variance τ2. Accordingly, Yi ∼N (θi , s2i ) and θi ∼N (µ,τ2) (Choi et al., 2003).
In this manner, large studies are capable to describe more precise estimations
than smaller studies, measuring the overall mean taking into account all the
effect sizes. This way avoids that larger studies dominate on the smaller studies.
μ
ε
ε
i
i
Dataset 2
Dataset 1
V1
V2
T
2
Figure 2.4: REM model
Schematic of the REM model [adapted from (Borenstein et al., 2010)].
The REM model is depicted in Figure 2.4 with an example of a disease with
two gene expression datasets or studies (V1 and V2). For each gene, the overall
mean of the effect size under study is represented by µ, a measure of the average
differential expression for that gene. The observed effect size for study i is given
by the following equation:
Yi =µ+²i +φi (2.4)
where φi is the difference between the distribution mean (µ) and the true mean
(θi ) for each study i : φi = θi −µ. And ²i is the difference between the true mean
for each study i (θi ) and the observed mean (Yi , Equation 2.4) for the study i :
²i = Yi −θi .
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On one hand, FEM model considers as true, only sampling error as the reason of
variation among effect sizes in the studies under the meta-analysis. Hence, this model
is plausible when the studies are close replications of one another (i.e., using similar
procedures, measures, etc.). On the other hand, in the REM model is assumed that
the studies will differ not only because they have different samples or participants,
but also because of divergences in the way they are conducted. Thus, this model is
plausible when variation among the studies is evident.
Gene expression normalization
Match
Merge
Filter
Estimation
effect sizes
FEM REM
Fisher's exact test (DEGs)
Figure 2.5: The meta-analysis workflow following the R MetaDE package (Wang
et al., 2012).
We have followed the pipeline presented in Figure 2.5. Before doing the meta-
analysis for each disease, the data must be preprocessed to assess the effect sizes and
variances. In this manner, since multiple probes within each microarray platform
match to the same gene, probes in each study need to be matched to official gene
symbols. When multiple probes match to an identical gene symbol, the probe that
presents the greatest inter-quartile range (IQR) is selected to represent the target gene
symbol. Large IQR represents greater variability, and thus, greater information con-
tent in the data. This is done by using Met aDE .match function from the R MetaDE
package (Wang et al., 2012). Then, we have filtered out genes not present in all the
studies, and genes with very low gene expression that are identified with small average
expression values across the majority of studies by using the Met aDE .mer g e and
Met aDE . f i l ter functions from the R MetaDE package (Wang et al., 2012) respec-
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tively. Finally, the effect sizes and the corresponding sampling variances have been
calculated for every gene of each study of each disease, following the formulas and the
strategy presented in Choi et al. (2003), and they have been combined with FEM and
REM models by using the i nd .cal .ES and Met aDE .ES functions from the R MetaDE
package (Wang et al., 2012) respectively.
Accordingly, using the gene expression normalized data (Section 2.4.2), microar-
ray meta-analyses have been undertaken for each disease independently using the
MetaDE R package (Wang et al., 2012), using both models, FEM and REM. MetaDE
implements meta-analysis methods for differential expression analysis, and we have
used the FEM model (Choi et al., 2003). Similar results are obtained with the REM ap-
proach, which allows heterogeneity in the effect sizes between the different datasets.
In this manner, the microarray meta-analyses led to the identification of genes
up- and down-regulated in each disease, and significant DEGs are selected as those
displaying a FDR corrected p-value (q-value) < 0.05 (in both FEM and REM cases).
Four other q-value cutoffs (0.005, 0.0005, 0.00005 and 0.000005) are also selected to
validate our results on more stringent DEGs sets (see Appendix A). We only present
here the cutoffs corresponding to FEM case, for simplify.
2.4.4 Comparisons of DEGs between the different diseases (Step 4)
Once the meta-analysis is done, for each cancer and CNS disorder sets of differen-
tially expressed genes up- and down-regulated are obtained. Accordingly, each CNS
disorder’s DEGs are compared to each cancer type’s DEGs. This is, the number of
DEGs common between each CNS disorder and each cancer type are calculated (in
two cases: up-regulated and down-regulated). The same strategy is done with each
CNS disorder and cancer, with each of the control diseases.
Then the significances of the overlaps between the DEGs are assessed by a one-
tailed Fisher’s exact test. The Fisher’s exact test assesses the difference between
the data observed and the data expected, considering the given marginal and the
assumptions of the model of independence. In this case, it calculates whether the
genes in common between genes up-regulated in a certain kind of cancer and genes
down-regulated in a CNS disorder are significantly different. The output of the Fisher’s
exact test is corrected for multiple testing by the Bonferroni approach. If multiple tests
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of the same hypothesis are done, the chance of finding one or more of the tests to be
positive increases. Thus, correction by false discovery rate (FDR) is fundamental and
is used in multiple hypothesis testing to correct for multiple comparisons. The same
procedure is applied for cancers, CNS disorders, and asthma, HIV, malaria, dystrophy
and sarcoidosis (Figure 2.10). The background number of genes necessary for the
Fisher’s test is set to 14,538.
2.4.5 GSEA analyses (Step 5)
GSEA (Gene Set Enrichment Analysis) is a computational method that determines
whether an a priori defined set of genes shows statistically significant, concordant
differences between two biological states (e.g. phenotypes). For each CNS disorder
and cancer type independently, a gene set enrichment analysis is undertaken using
GSEA (Subramanian et al., 2005) on the output of the meta-analyses, and focusing
on KEGG (Ramanan et al., 2012), Biocarta (Bio) and Reactome (Matthews et al., 2009)
pathway databases.
Significant pathways are selected as those with q-value (FDR) < 0.05. Significant
pathways in each disease are then compared to each others, and a network of pathways
is built (Figure 2.13, Figures A.5 and A.6). For the KEGG pathways, further classification
of the pathways in Metabolism, Genetic Information Processing, Cellular Processes,
Environmental Processes and Organismal Processes, as provided by KEGG (keg) is
done (Figure 2.14). Pathways corresponding to Human Diseases have been discarded.
2.5 Results
Following the scheme proposed (Figure 2.2), we present below the performance
of the data selection described in Step 1 (Section 2.4.1). The outcome of the princi-
pal hypothesis regarding the inverse comorbidity between cancer and CNS disorders
once data is preprocessed, and meta-analysis with FEM and REM strategies is also
presented. We also show the result when the DEGs in cancer and pseudo-control
disorders, and CNS and pseudo-control disorders are compared and analyzed respec-
tively. The biological pathways enriched in the DEGs analyzed are also presented.
At last, several potential candidates are proposed that could shed light on further
research studies.
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2.5.1 Microarray data selection through MetaQC
For each disease, the marginal impact of a meta-analysis on DEGs has been com-
puted while studies are sequentially included into the meta-analysis. Figure 2.6 shows
the number of DEGs for each disease, corrected by FDR = 0.05, when studies are added
sequentially in the meta-analyses in the order of standardized mean rank (SMR) score.
For each study, in x-axis the accumulation of the series of meta-analysis is represented.
The order of addition follows the SMR score computed by MetaQC (Kang et al., 2012).
Y-axis represents the number of DEGs detected. In all of them, the number of DEGs,
under FDR=0.05, increases as more studies are added. Thus, including these addi-
tional studies to the meta-analysis provides an increased statistical power to detect
more DEGs. This score is internally computed as SMR = mean r ank o f al l QC measur esnumber o f studi es .
In this way, this means that the selected data is adequate and suitable for a meta-
analysis.
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Figure 2.6: Marginal impacts on meta-analysis for DEGs detection in a) SCZ b) AD c)
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2.5.2 Significant inverse comorbidity between cancer and
CNS disorders
As an example, we present here a gene expression profiling as a measurement
of the activity (i.e., the expression) of thousands of genes at once, to create a global
picture of how the gene expression is in each disease. Figure 2.7 shows the pattern of
gene expression values when an Alzheimer’s disease and a prostate cancer data sets
are analyzed. Green cells indicate reduced expression, red cells are actively expressed.
It can be observed that there are many parts within the plot having an inverse behavior
between the gene expression in prostate data set (characterized by a red rectangle in
the figure), and the gene expression in Alzheimer’s disease (characterized by a blue
rectangle in the figure).
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Figure 2.7: Heat map of the gene expression values in an Alzheimer’s disease (in
blue) and a prostate cancer (in red) data set.
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For each CNS disorder and cancer type independently, we have undertaken meta-
analyses from a large collection of microarray gene expression datasets to identify the
genes that are significantly up- and down-regulated in disease when compared with
their corresponding healthy control samples. Then, the DEGs of the CNS disorders
and cancer types have been compared to each others.
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Figure 2.8: Comparisons of DEGs associated with CNS disorders and cancers with
FEM.
Figures 2.8 and 2.9 contain the comparisons of DEGs associated with each pair
CNS disorder–cancer, after having applied the data with FEM and REM respectively.
Each cell includes the p-value of the significance of the DEGs overlap between the pair
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of diseases. Cells are colored according to the significance of the overlaps (Fisher’s
exact test, Bonferroni correction for multiple testing, see Section 2.4.4). Grey cells
correspond to non-significant overlaps (q-value > 0.05). The number of genes in
common (overlapping genes) between the pair cancer–CNS disorder is included in
each cell. Below the description of each disorder, the numbers of the total genes dif-
ferentially expressed are also represented. There are significant overlaps between the
DEGs up-regulated in CNS disorders and those down-regulated in cancers. Similarly,
DEGs down-regulated in CNS disorders overlap significantly with DEGs up-regulated
in cancers (Figures 2.8 and 2.9). It is also observed similar outcomes with the two
different strategies, FEM and REM, even though with REM the results have lower
significance values, but still very significant.
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Figure 2.9: Comparisons of DEGs associated with CNS disorders and cancers with
REM.
Significant overlaps between DEGs deregulated in opposite directions in CNS
disorders and cancers are still observed while setting more stringent cutoffs for the de-
tection of DEGs (q-values lower than 0.005, 0.0005, 0.00005 and 0.000005 by FEM, see
Appendix A). A significant overlap between DEGs deregulated in the same direction is
only identified in the case of CRC and PD upregulated genes with both methodologies
(Figure 2.8).
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2.5.3 Non-significant comorbidity between other diseases
Then, we have compared the CNS disorder and cancer DEGs with DEGs of a
number of diseases for which, to our knowledge, inverse comorbidities have not been
reported in the literature. These diseases, for which large enough expression datasets
are available, included asthma, HIV, malaria, dystrophy and sarcoidosis.
Significant overlaps are observed between DEGs of all these diseases and DEGs
of CNS disorders or cancers (Figures 2.10 and 2.11). However, patterns of expression
deregulation in opposite directions, which are found to be characteristic of the relation
between CNS disorders and cancers, are in most cases not observed with these other
genetic or infectious diseases (Figures 2.10 and 2.11).
Figures 2.10a and 2.11a contain the comparison of DEGs associated with each
pair cancer–control diseases with FEM and REM approaches respectively. Each cell
includes the p-value of the significance of the DEGs overlap between the pair of
diseases. Cells are colored according to the significance of the overlaps (Fisher’s
exact test, Bonferroni correction for multiple testing, see Section 2.4.4). Grey cells
correspond to non-significant overlaps (q-value > 0.05). The number of genes in
common overlapping between the pair cancer–other diseases, is included in each cell.
Below the description of each disorder, the numbers of the total genes differentially
expressed are also represented. Figures 2.10b and 2.11b contain in the same way, the
comparisons of DEGs associated with each pair CNS disorder–control diseases.
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Figure 2.10: Comparisons of DEGs by FEM between a) cancer and asthma, HIV,
malaria, dystrophy and sarcoidosis. And b) CNS disorders and asthma, HIV, malaria,
dystrophy, and sarcoidosis.
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Figure 2.11: Comparisons of DEGs by REM between a) cancer and asthma, HIV,
malaria, dystrophy and sarcoidosis. And b) CNS disorders and asthma, HIV, malaria,
dystrophy and sarcoidosis.
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An interesting observation is that the overlaps are predominantly significant be-
tween DEGs deregulated in the same directions, i.e., between up-regulated genes
of the different diseases (or conversely between down-regulated genes), and could
be a signature of putative positive comorbidities. It is to note that malaria and CNS
disorders DEGs present overlaps between DEGs deregulated in opposite directions,
contrarily to what is detected for other diseases. This observation will require addi-
tional research. Overall, these observations support the indication of a signature for
inverse comorbidity in gene expression deregulations in opposite directions.
2.5.4 PIN1 as putative candidate
The PIN1 gene has been proposed previously as a putative link between the patho-
geneses of AD and cancer (Behrens et al., 2009). Through the isomerization of a
proline preceded by phosphorylated Ser/Thr residues, the PIN1 protein is known to
be a key regulator of cell division (Lu, 2004). PIN1 gene is typically over-expressed in
human cancers and as such, it has been assessed as a potential target for anticancer
drugs (Behrens et al., 2009). In addition, PIN1 is depleted in AD, it has been shown to
restore the function of the phosphorylated tau protein, and mouse models in which
this protein is knocked-down present neurodegenerative phenotypes (Lu, 2004; Liou
et al., 2011).
Figure 2.12: The PIN1 protein structure.
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Our transcriptomic meta-analyses confirm and extend these observations as the
expression of PIN1 is down-regulated in AD and PD, and up-regulated in CRC. Another
interesting case is the ATP13A2 gene, involved in the intracellular cation homeostasis.
ATP13A2 is part of a list established by Devine et al. of familial PD genes frequently mu-
tated in cancers (Devine et al., 2011). Indeed, loss-of-function mutations of ATP13A2
have been associated with early-onset Parkinsonism, and somatic mutations have
been independently observed in cancer (Devine et al., 2011). We identified ATP13A2 as
down-regulated in AD and PD, and up-regulated in the three cancer types considered.
2.5.5 Towards potential candidate links
In the light of these findings, our computational approach appears to be capable
of identifying candidate genes potentially associated with inverse comorbidity. In
particular, 74 genes may be of interest since they are simultaneously down-regulated
in the three CNS disorders and up-regulated in the three cancer types examined
(included in Table 2.3). RNA splicing (four genes: PPIH, LSM4, NUDT21, SRSF2) and
aminoacyl t-RNA ligases (three genes: FARSA, IARS, IARS2) represent particularly
interesting functions.
We also pinpoint two genes involved in lipid biogenesis (ACLY and MECR), and
other two are transcription factors: NME2 and TFCP2, for which a genetic association
with AD is debated (Cousin et al., 2011). Finally, two other genes, OAZ2 and the sper-
mine synthase SMS, are dedicated to polyamine metabolic processes. Interestingly,
defects in the spermine synthase gene are associated with the X-linked mental retar-
dation Snyder-Robison syndrom (Cason et al., 2003), and spermine is often the most
abundant polyamine in cancers (Huber and Poulin, 1995). The polyamine metabolic
process hence may play a role in the pathological mechanisms of both CNS disorders
and cancers.
Conversely, 19 genes are simultaneously upregulated in the three CNS disorders
and downregulated in the three cancer types examined (included in Table 2.4), in-
cluding for instance six genes involved in signal transduction (TNFRSF1A, CDKN1A,
NFKBIA, PTH1R, IL4R, MID1). Particularly, NFKBIA is an interesting candidate be-
cause this gene is often deleted in glioblastoma (Bredel et al., 2011), although to our
knowledge no mutations or polymorphisms have been described in CNS disorders.
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PPIAP11, IARS, GGCT, NME2, GAPDHP1, CDC123, PSMD8, MRPS33, FIBP,
OAZ2, IARS2, SLC35B1, APOO, TMEM189-UBE2V1, VDAC1, TMED3, SMS, ,
DNM1L, PRPS1, SRSF2, TMEM14D, TOMM70A, ATP6V1C1, NUP93, MRPL15,
UBA5, PPIH, SMYD3, NIT2, SRD5A1, NUDT21, MRPL12, EEF1E1, MRPS7, TTPAL,
BZW1P2, RP11-552M11.4, TSN, MECR, ZWINT, RPRD1A, UCHL5, NHP2P2, TFB2M,
FEN1, CGREF1, IMPAD1, ARL1, , ACLY, MRPL42, LSM4, KPNA1, TIMM23B, RP11-
164O23.5, RP11-762H8.2, FARSA, MRPL4, API5, RP3-425P12.4, RFC3, RANBP9,
TFCP2, GMDS, CCNB1, TMEM177, GUF1, HSPA13, NMD3, GCFC2, TUBGCP5,
TBCE, YKT6, PHF14, BRCC3
Table 2.3: DEGs significantly down-regulated in the three CNS disorders and up-
regulated in the three cancer types (q-value < 0.05) (FEM approach).
MT2A, MT1X, NFKBIA, AC009469.1, DHRS3, CDKN1A, TNFRSF1A, CRYBG3,
IL4R, MT1M, FAM107A, ITPKC, MID1, IL11RA, AHNAK, KAT2B, BCL2, PTH1R,
NFASC
Table 2.4: DEGs significantly up-regulated in the three CNS disorders and down-
regulated in the three cancer types (q-value < 0.05) (FEM approach).
2.5.6 Biological pathways in cancer and CNS disorders
In order to enhance the functional interpretation of the molecular bases of inverse
comorbidity, we have broadened the comparisons of expression deregulations by
considering pathways instead of individual genes (Ramanan et al., 2012).
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We have identified the pathways that were significantly up- and down-regulated
(see Section 2.4.5) in each of the six diseases independently. Among all the KEGG
pathways (Kanehisa et al., 2008) significantly up- and down-regulated in the 6 diseases
(CRC, PC, LC, SCZ, AD, and PD), 30 are shared by CNS disorders and cancers (i.e.,
significantly deregulated in at least 1 CNS disorder and 1 cancer type). Strikingly, of
these 30 shared pathways, 24 (80%) are deregulated in opposite directions in CNS
disorders and cancers (Figure 2.13, 63% and 86% for the Biocarta (Bio) and Reactome
(Matthews et al., 2009) databases, respectively, Figures A.5 and A.6).
In Figure 2.13 KEGG pathways identified by GSEA which are significantly up- and
down-regulated in each disease (cancer and CNS disorders) are represented in a
network. The significant pathways have been compared between the 6 diseases and
combined in a network representation. Node pie charts are colored according to
the pathway status as cancer up-regulated (yellow), cancer down-regulated (blue),
CNS disorder up-regulated (green), and CNS disorder down-regulated (red). The
green–blue and yellow–red associations thus correspond to pathways deregulated
in opposite directions in CNS disorders and cancers. Pathway labels are colored
according to their classifications provided by KEGG as: Metabolism (green), Genetic
Information Processing (yellow), Cellular Process (pink), Environmental Information
Processing (red), and Organismal Systems (dark red).
The p53 signalling pathway is an anticipated candidate for deregulations in these
diseases and for a role in inverse comorbidity (Behrens et al., 2009). Indeed, deregula-
tions of the p53 signalling pathway are associated with the initiation and progression
of cancers, while recent studies also point to a role for this pathway in CNS disor-
ders (Tabarés-seisdedos and Rubenstein, 2013). As such, specific polymorphisms in
the TP53 gene are found in SCZ patients (Tabarés-seisdedos and Rubenstein, 2013).
Although the TP53 gene itself does not appear to be differentially regulated in our
analysis, the p53 pathway is upregulated in CRC and LC, while it is downregulated in
PD, AD and SCZ (Reactome database; Figure A.6).
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Figure 2.13: KEGG pathways significantly up- and down-regulated in each disease
have been identified using the GSEA method (q-value<0.05).
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Similarly, the Wnt pathway may be particularly relevant as mutations in the genes
encoding APC and Beta-catenin, elements of the Wnt pathway, have been described
in CRC, while beta-amyloid induced neurotoxicity in AD has been associated with
impaired Wnt signalling (Lu, 2004; Behrens et al., 2009). Furthermore, alterations in
the Wnt signalling pathway are known to be involved in SCZ (Okerlund and Cheyette,
2011). In our meta-analyses, we have found the Wnt pathway to be downregulated in
AD and PD, and upregulated in CRC (Reactome database; Figure A.6).
Aside the Wnt and p53 pathways, our analysis reveals other pathways related to
protein folding and protein degradation displaying patterns of down-regulation in
CNS disorders and up-regulation in cancers, and that may be relevant for inverse
comorbidity. For instance, the Ubiquitin/Proteasome system is consistently downreg-
ulated in CNS disorders and upregulated in cancers according to the three pathway
databases analyzed (Figure 2.13, Figures A.5 and A.6). The inverse relationship be-
tween the levels of expression deregulations of these pathways possibly suggests
opposite roles in CNS disorders and cancers.
Figure 2.14: The KEGG pathways identified by the GSEA analysis (FEM).
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Figure 2.14 shows the descriptions of the KEGG pathways identified by GSEA
analysis as significantly up- and down-regulated in CNS disorders, in cancers, and
simultaneously up-regulated in CNS disorders/down-regulated in cancers, and down-
regulated in CNS disorders/up-regulated in cancers (q-values < 0.05, Figure 2.13).
They are classified as Metabolism (in green), Genetic Information Processing (in
yellow), Cellular Process (in pink), Environmental Information Processing (in orange)
and Organismal Systems (in brown), according to the classification provided by KEGG
This detailed examination of the KEGG pathways deregulated in opposite direc-
tions in CNS disorders and cancers finally reveale that 89% of the KEGG pathways
that are up-regulated in cancers and down-regulated in CNS disorders are related
to Metabolism and Genetic Information Processing (Figure 2.13, Figure 2.14). By
contrast, the pathways down-regulated in cancers and up-regulated in CNS disorders
are related to the cell’s communication with its environment (Environmental Infor-
mation Processing and Organismal System; Figure 2.13, Figure 2.14). Hence, global
regulations of cellular activity may account for a protective effect between inversely
comorbid diseases.
2.6 Conclusions
We have developed a computational approach in order to compute transcriptomic
meta-analyses in complex disorders. Particularly, between some types of cancer and
CNS disorders in the context of the inverse comorbidity, since a genetic base exists.
This complex biomedical problem has been studied at the medical level, based on
solid population and epidemiological studies, but there is little information at the
molecular level. We here advance for the first time evidences of the genetic base
associated with inverse comorbidity at the molecular level, analyzing a relevant aspect
within Genetics, i.e. gene expression. A novel, remarkable, and significant overlap
is observed between the genes up-regulated in cancers and down-regulated in CNS
disorders, as well as between the genes down-regulated in cancers and up-regulated
in CNS disorders. These gene expression deregulations in opposite directions are
also observed at the level of pathways, and point to specific genes and functions the
deregulation of which could promote CNS disorders and simultaneously lowers the
initiation or progression of cancer.
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A molecular interpretation of the inverse comorbidity between CNS disorders and
cancers could be that the down-regulation of certain genes would at the same time
increase the risk of developing CNS disorders, while reducing the risk of developing
cancer. The up-regulation of other genes would reduce the risk of developing CNS dis-
orders and increase the risk of developing cancer. But we might be cautious, because
there are several real limitations: the gene expression data analyzed is derived from
different tissues, and from different patients. For instance, we do not know whether a
gene up-regulated in Alzheimer’s disease is down-regulated in the corresponding lung
tissue in the same individual, and this is the reason for not developing cancer (and
the other way around). The cases and controls data from the neurological disorders
correspond to different individuals, since it is not possible to take a normal brain
tissue from the patient under study. Indeed, the gene expression may vary across the
different parts of the brain. Moreover, in cancer data, normal and tumoral cells are
mixed and even though control tissue data are used, part of the information might
be lost. There is a large variability within the individuals and the diseases under
study, they are not homogeneous since there are many cancer subtypes and in such a
manner, many differential behavior subtypes. Thus, not all the patients suffering a
disease will have the same grade of protection.
New data and further analyses will be necessary to conclude to a direct protective
effect of gene expression deregulations in cancer-prone tissues of patients suffering
from CNS disorders. Indeed, the DEGs analyzed in this study are computed for each
disease in the corresponding affected tissues, and cannot be extrapolated to gene
expression deregulations in other tissues of the same patients. However, despite
these limitations, the identification of antagonistically deregulated genes and path-
ways in complex diseases that have been previously described as inversely comorbid
provides, to our knowledge, the first systematic insights into the possible molecular
basis of these associations. The principal result we here present tries to open a new
perspective.
It suggests that the up-regulation of a set of genes or processes could increase the
incidence of CNS disorders and simultaneously lower the chances of developing can-
cers, while the down-regulation of another set of genes or processes could contribute
to a decrease in the incidence of CNS disorders while increasing the cancer risks. The
individuals delivering post-mortem brain samples in CNS disorders, or tumor tissues
in the case of cancers, are likely to have received drug treatments. Hence, the observed
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expression deregulations could be the consequence of the drugs administered to the
patients. If this is the case, it can be hypothesized that some of the drugs used to treat
CNS disorders might be able to revert the expression of a number of cancer genes. In
this context, the repurposing of drugs from the CNS disorders to the cancer field could
open new therapeutic avenues. Indeed some punctual observations have been made.
For example, the thioridazine, an anti-psychotic drug antagonizing the dopamine
receptor and potentially able to alter physiological states and expression patterns,
have been reported to target cancer stem cells selectively (Sachlos et al., 2012). An-
other example is a recent work published by Yale School of Medicine researchers
reported in the journal Annals of Neurology. They have proved that a failed drug on
treating solid tumor appears to restore synaptic connections and reduced inflamma-
tion, and the animal’s memory, a hallmark of Alzheimer’s disease. In this manner,
memory and the connections between brain cells are restored in mice with a model
of Alzheimer’s given this experimental cancer drug (Kaufman et al., 2015). Despite
these two last observations, the effect of the drugs cannot explain by themselves the
observed inverse comorbidity. For instance, several works have noted that the relatives
of patients suffering schizophrenia have less probability of developing any cancer (Gal
et al., 2012; Ji et al., 2013), suggesting that genes associated with schizophrenia might
confer reduced cancer susceptibility. There is a genomic and molecular base that
determines the behavior of the individual in general, and the effect of the drug in each
one, in particular. More data is necessary to be able to establish a relationship between
some drugs and the genetics behind the inverse comorbidity, and the observed gene
expression patterns.
From the computational and statistical point of view, similar results have been
obtained with both FEM and REM approaches. They do not only use the effect size,
the variance is essential when studying the variability within the study and across the
datasets. However, meta-analytic strategies such as Fisher, use only p-values and they
do not take into account the variance for instance. FEM and REM are very referenced
as the most appropriate to do a microarray meta-analysis. The use of combination of
p-values (Fisher) would be suitable when gene expression raw data was available, but
a list of genes with the associated p-values (usual in the published works).
Finally, the analyses of inverse expression deregulations could serve as a new ap-
proach to investigate relations between complex diseases, of which the ones reported
here between CNS disorders and cancers can be considered as an initial example.
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3 Study of the stability of protein
interaction networks in cancer and
CNS disorders
3.1 Summary
Molecular networks provide a powerful tool for the study of biomedical systems, in
particular several studies have detected alterations of the network structure associated
to disease states. Here we propose that diseases cannot only alter the structure of
the network but also its stability. To evaluate network stability we have developed a
new methodological framework. Our approach takes advantage from the classical
deterministic Simulated Annealing algorithm to work with discrete states. Adjusted
energy values are used to compare the network stability in disease and control states.
The results show that cancer networks are less stable than the Alzheimer’s disease
ones. These results can be interpreted in terms of our previous observations on cancer
and Alzheimer’s disease inverse comorbidity, i.e., Alzheimer’s disease patients have
lower than expected risk to suffer cancer.
3.2 Introduction
CNS or neurological disorders and cancer are two current global health priorities.
Interestingly, epidemiological evidence is mounting that patients with certain neuro-
logical disorders, including those suffering from schizophrenia (SCZ) and Alzheimer’s
disease (AD), have a lower than expected tendency to develop some forms of cancer
(Behrens et al., 2009; Tabarés-Seisdedos et al., 2011; Behrens et al., 2012; Tabarés-
seisdedos and Rubenstein, 2013). Hence, we performed a systematic meta-analysis of
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gene expression in order to investigate the molecular mechanisms that might underlie
such inverse comorbidity, identifying genes and pathways differentially expressed
in neurological disorders and some types of cancer (Ibáñez et al., 2014). Interest-
ingly, we found a common set of genes and biological processes that were apparently
deregulated in opposing directions in cancers and neurological disorders.
Here, we set out to broaden our understanding of the molecular basis underlying
the differences between cancers and neurological conditions. As such, and given
that the central dogma of molecular biology dictates that information flows from
genes to proteins via RNA (Crick, 1970) (see Figure 1.3), we have integrated gene
expression data with Protein-Protein Interaction Networks (PPINs) in order to study
these differences in terms of network organization rather than at the level of individual
genes. Gene expression data informs whether a gene that encodes a given protein
is active or not. Yet proteins function in the context of their interactions with other
proteins, interactions that are described in PPINs in which each protein represents
a node in the network. The strategy of combining PPINs with gene expression is
artificial, since the networks that are available correspond to a particular state rather
than diseases, individuals or conditions.
In PPINs, it is assumed that proteins corresponding to genes that are not active (i.e.
unexpressed) will not interact with their potential partners. Therefore, the production
of RNA by genes is commonly used as a proxy of the activity of the gene, and this
is correlated with the activation of molecular systems within PPINs that underlie
physiological and developmental processes. Indeed, in many cases, deregulation of
gene expression provokes dramatic phenotypic changes, as occurs in several diseases
(Kaern et al., 2005).
Protein interaction maps have been used to study the molecular organization of
cellular systems and the perturbations in them created by disease. PPINs reflect the
functionality of interacting proteins and for example, the consequence of a single gene
deletion in the yeast Saccharomyces cerevisiae would appear to depend on the position
of the gene product within the PPIN (Jeong et al., 2001). Thus, the most important
proteins for a cell’s survival are highly connected (Jeong et al., 2001; Wuchty and
Almaas, 2005), and altering them has profound effects on the PPIN. In terms of cancer,
it is thought that cancer related proteins correspond to central hubs and that they are
highly connected within networks (Jonsson and Bates, 2006). Indeed, the genomic
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and network characteristics of genes mutated in cancer seem to confirm that these
genes tend to encode central hubs within PPINs (Rambaldi et al., 2008). In addition,
PPINs have been used as background layers when mapping gene expression data in
order to gain information about the state of the nodes and their possible dynamics
(Chuang et al., 2007; Pujana et al., 2007; Hudson et al., 2009; Milanesi et al., 2009;
Komurov and Ram, 2010; Schramm et al., 2010; Teschendorff and Severini, 2010; West
et al., 2012; Börnigen et al., 2013; Liu et al., 2013b; van Pel et al., 2013). For example,
genes that are over expressed in lung cancer are more strongly connected than those
that are suppressed or selected at random (Wachi et al., 2005).
We here hypothesize that PPINs related to cancer are more unstable than those
based on neurological data. This may be because there are more active interactions
between cancer related proteins and thus, a mutation or change in any of these
would cause an important destabilization of the network. By contrast, proteins cor-
responding to genes affected in neurological disorders have less active connections
and consequently, they are less susceptible to destabilization. In this context, we
present an approach based on the combination of gene expression data and PPINs
to study the relationship between cancers and neurological disorders. To achieve
this, we associate each protein (or node) in the network with a state that is directly
related to the level of expression of the corresponding gene. The expression data used
is derived from a large series of experiments carried out on cancer and neurological
disorders in humans, information that makes the PPINs disease specific, and that
allows comparative studies to be performed.
In terms of the computational methodology to study the differences between
disease specific networks, we have found an appropriate equivalence in the determin-
istic Simulated Annealing (DSA) algorithm proposed previously (Duda et al., 2001).
The DSA algorithm was designed to find the optimal solution inspired by different
biological or physical phenomena. The DSA is based on the shifting of metals from
an unstable state as a liquid to a stable solid state, a process mediated by a decrease
in the temperature of the material. These transformations can be simulated by the
evolution of the states of interconnected network nodes that evolve until an optimal
solution with minimal energy is reached. This evolution is controlled through an
energy minimization process that determines the network’s stability as the energy
decreases. Therefore, lower energies correspond to greater stability.
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Inspired by the DSA algorithm, we have designed and implemented a new method
to measure the stability of PPINs based on an energy function. In this approach the
concept of stability differs from that in the original DSA, in which the network evolves
towards states with different stabilities via temporal transitions or another equiva-
lent value (Pajares and de la Cruz, 2004; Sánchez-Lladó et al., 2011). The proposed
approach used in this study computes the energy based on existing interactions and
it computes the energy difference between two states, such as disease and control
samples. In this manner, the temporal aspect of the original DSA is reduced to the
comparison between a reference and a new model. The reference state can be con-
sidered to be equivalent to the initial state and the new model as a single progressive
step. Furthermore, any simulated annealing process (DSA or probabilistic) is driven
by an optimization process in order to achieve stable states (minimum energy values).
By contrast, since only one transition is considered in our approach, there is no opti-
mization process involved and local minima energy are avoided. These substantial
differences from the original DSA are introduced to make it possible to perform a large
scale systematic comparison of networks associated to cancer, neurological disorders
and normal controls for which the information available comes from experiments
carried out at only one time point, representing a single state of these conditions.
3.3 Materials
The protein interaction and gene expression data used in this study are obtained
from PPIN and gene expression data sets.
3.3.1 The protein–protein interaction network
We have used the human PPIN from the Protein Interaction Network Analysis
database (pin) version October 2011 (Wu et al., 2009). PINA is an integrated platform
of PPIN data that has been extracted from six different public databases: IntAct, MINT,
BioGRID, DIP, HPRD, and MIPS/MPact. It includes self-interactions, interactions
predicted by computational methods, and interactions between human proteins and
proteins from other species. Moreover, it has recently been used in other similar
studies (Xia et al., 2011), in which they have compared protein interactions network
characteristics of cancer proteins to see whether cancer proteins interact strongly
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within the human PPIN.
Besides the PINA network, we also have used two additional PPINs in order to
guarantee that a similar outcome is obtained: The Human Protein Reference Database
(HPRD), version April 2010 (hpr) that contains pairs of human protein interactions
based on experimental evidence from the literature and that has been used in several
studies (Teschendorff and Severini, 2010; West et al., 2012), and the Human Integrated
Protein-Protein Interaction rEference (HIPPIE) version September 2014 (hip) that
incorporates a human PPI dataset with a normalized scoring scheme, integrating
data from HPRD, BioGRID, IntAct, MINT, Rual05, Lim06, Bell09, Stelzl05, DIP, BIND,
Colland04, Lehner04, Albers05, MIPS, Venkatesan09, Kaltenbach07, and Nakayama02.
We have selected the interactions from these PPINs with a curated score above 0.73 in
order to be confident that the pairs of proteins interact (Schaefer et al., 2012).
3.3.2 Gene expression data sets
Measuring gene expression with microarrays is now a common molecular biology
approach in biomedicine, making it possible to simultaneously measure the rela-
tive expression of thousands of genes under different experimental conditions (mit,
2002). Thousands of gene expression data sets are available in public databases, each
containing a description of the corresponding biomedical origin of the sample, the
analytic procedures followed, and the experimental results in terms of expression (i.e.,
the amount of RNA produced for each gene in the genome).
Raw experimental gene expression data (CEL files) for ovarian, colon, liver and
kidney datasets have been downloaded from the Barcode human transcriptome repos-
itory (bar), and for the SCZ and AD datasets they have been downloaded from the
NCBI GEO omnibus (geo) and Stanley Medical Research Institute Online Genomics
Database (smr) (SMRI). Importantly, each dataset corresponds to a collection of dis-
ease and control samples. For the analysis we have filtered out the cases with too
few disease/control cases (less than 9) and we only have used those produced in the
same platform (Affymetrix array GeneChip Human Genome U133 Plus 2.0), render-
ing information on 23,945 human genes. This technical platform has been widely
used, and using the same platform on all data sets facilitates comparative studies and
ameliorates potential experimental errors. Table 3.1 summarizes the data included in
this study. The platform field indicates the name of the microarray platform used in
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the gene expression dataset, the sample size the total number of patients (cases and
controls) included in each dataset, and the source the identifier of the experimental
dataset in GEO and SMRI repositories.
Table 3.1: Gene expression datasets.
Tissue Platform
Sample
Size
Source
Alzheimer’s disease
Entorhinal Cortex HG-U133Plus2 23 GSE5281
Hippocampus HG-U133Plus2 23 GSE5281
Medial Temp. Gyrus HG-U133Plus2 28 GSE5281
Posterior Singulate HG-U133Plus2 22 GSE5281
Primary Visual Cortex HG-U133Plus2 31 GSE5281
Superior Frontal Gyrus HG-U133Plus2 34 GSE5281
Hippocampus HG-U133Plus2 24 GSE1297
Schizophrenia
Postmortem cerebellum HG-U133Plus2 28 GSE4036
Postmortem frontalBA46
cortice
HG-U133Plus2 55 Dobrin
Postmortem hippocampus
(CA1)
HG-U133Plus2 41 Laeng
Postmortem thalamus (MD) HG-U133Plus2 26 Kemether
Colorectal cancer
Colon tissue HG-U133Plus2 33
GSE4183
GSE7307 (GSM175905)
GSE2109
Colon tissue - stages HG-U133Plus2 43 GSE17537
Ovarian cancer
Ovary tissue HG-U133Plus2 278
GSE9891
GSE2109
GSE9890
GSE3526
GSE7307
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Table 3.1 – Gene Expression datasets
Tissue Platform
Sample
Size
Source
Liver cancer
Liver tissue HG-U133Plus2 129
GSE6222
GSE9829
GSE9843
GSE6956
GSE11045
GSE7307
Liver tissue - stages HG-U133Plus2 8 GSE6764
Kidney cancer
Kidney tissue HG-U133Plus2 119
GSE2109
GSE11151
GSE12090
GSE8050
GSE9489
GSE9493
GSE11045
GSE11151
For each disease, several datasets are included. For AD and schizophrenia we
have included gene expression studies from different parts of the brain, because the
expression of the genes could vary depending on the region of the brain. For colorectal
and liver cancer, additional datasets have been included to study the stability of the
PPINs during the cancer evolution (see Section 3.5.4).
3.4 Methods
In order to study the stability of the PPIN in cancer, neurological and normal
samples, we have implemented an original method inspired by the well-known DSA
approach that has been customized to study neighbor-energy (nE). In this case, stabil-
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ity describes a network state that is not significantly altered, even when fundamental
properties have changed or perturbations have been introduced. From the biolog-
ical point of view, network instability could reflect a situation where mutations in
a key protein involved in many interactions will alter several associated biological
processes.
A filtered PPIN (Section 3.4.1), and preprocessed and normalized gene expression
data (Section 3.4.3) for three different conditions (cancer, normal and neurological
disorders), are the inputs for our approach (Section 3.4.4). A scheme of the workflow
is presented in Figure 3.1, where preprocessing and filtering are clearly represented
as two separate modules. The first four boxes represent the selection, inclusion and
preparation of the data (gene expression and PPIN) that correspond to the input of
our proposing approach.
Figure 3.1: Proposed flow chart.
3.4.1 Protein–protein interaction network filtering
Data from the PINA network are filtered by requiring experimental evidence for
PPIs, removing redundancy and self-interactions, as well as interactions involving
proteins that are not from Homo sapiens. Thus, we only consider those interactions
between proteins that are also detected in the Human Genome U133 Plus 2.0 microar-
ray platform. The resulting filtered PINA network contains 10,650 proteins with 63,119
interactions. In Figure 3.2a a subnetwork of the filtered PPIN is shown.
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3.4.2 Sub-network related to synaptic vesicle cycle
A sub-network of proteins encoded by genes related to the synaptic vesicle cycle is
analyzed, retrieving proteins in the synaptic vesicle (SV) cycle from the KEGG pathway
(keg) (hsa04721 pathway id, version September 2014). The number of genes involved
in the SV cycle pathway are 63, and 50 out of 63 genes are detected in microarrays.
The resulting sub-network contains 50 proteins and 3,815 interactions.
3.4.3 Microarray gene expression preprocessing
Handling microarrays requires the preprocessing of each individual microarray to
estimate the expression of each gene in the array. Gene expression data from ovarian,
colon, liver and kidney cancers, and from SCZ and AD samples, are normalized
by frozen Robust Multiarray Analysis (fRMA) (McCall et al., 2012) from the R Affy
package (Gautier et al., 2004). Background-corrected gene intensities are obtained
by applying fRMA processes to each array individually, and accounting for probe
variability, batch effects, probe effects, array-to-array variability, and background
noise. The samples are then processed using Barcode (McCall et al., 2012) in order
to convert gene intensities into estimates of gene expression (Z-score, Figure 3.2b).
Additionally, gene intensities are mapped into a binary vector of “ones” and “zeros”
that denote whether a gene is expressed (1, when the Z-score is higher than a threshold
value: 4,98 by default) or not (0) in each sample (Figure 3.2b and Table 3.1: (McCall
et al., 2011; Zilliox and Irizarry, 2007). These values are used in Equation 3.1, in which
it is necessary to specify whether a gene is expressed or not.
To compare the Z-score between these diseases, we have normalized them using
the pnor m function of the R stats package to calculate the normal distribution func-
tion of each Z-score. This normalization step is commonly employed to avoid values in
a given range dominating other values. High Z-scores indicate intense gene expression,
while small Z-scores correspond to weak expression. For expressed genes, defining S
as the normalized Z-score, S = pnor m(Z − scor e), represents the probability of the
gene being expressed. When the gene is not expressed, S = 1−pnor m(Z − scor e)
indicates the probability of the gene not being expressed. These S values are used in
Equation 3.2. Hence, each state in the system would represent the significance (S)
of the expression of each gene (Figure 3.2b). In summary, for each disease we have
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associated a binary value reflecting whether the gene is expressed or not (one or zero,
respectively), attributing a value and a significance to the expression of each of the
10,650 genes in the network (Figure 3.2b).
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Figure 3.2: (a) Filtered PPI subnetwork. (b) Preprocessed and normalized gene
expression data. (c) Representation of the nodes in a PPIN sub-network and an
application of the algorithm to a PPIN sub-network.
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3.4.4 Approach inspired by simulated annealing algorithm
To study network stability we have adopted an approach based on the SA concept,
a probabilistic method that allows the global minimum of a generic cost function to
be found (S. Kirkpatrick et al., 1983; Cerny, 1985). This procedure reproduces the way
the structure of a solid reaches its minimum energy configuration through cooling,
becoming "frozen" at this minimum energy.
A full description of the DSA is included in Appendix B (Haykin, 1994; Duda
et al., 2001), which also follows a physical analogy based on a set of interconnected
nodes, each one with its associated state. During the cooling process forces between
interconnected nodes act on the structure, which evolves until each node reaches a
stable state. Thus, the nodes interacting with other nodes within the system influence
one another with a defined weight.
Our algorithm is inspired on the definition of a nE function that measures the
stability of the network, as well as on the general deterministic approach whereby a
lower nE is related to greater stability. In our case, using a nE function that decreases in
function of the interactions or over time does not make sense given the characteristics
of the biological problem. Indeed, our approach does not evolve through iterations or
time and thus, this part of the algorithm was not considered.
Our system is represented by a PPIN in which nodes represent proteins associated
to the expression of the corresponding gene (Si describes the significance (S) of a gene
i being expressed or not). Our approach is applied to estimate the dynamic structures
in the PPIN (Figure 3.2c), where Si represents the state of the node in the original DSA
approach, and the edges reflect the interactions existing between proteins. Each Wi j
represents the weight required (Equation 3.1), where Wi j is inversely associated to
the existence of the interaction between two proteins. If the two genes i and j are
both expressed, then the two corresponding proteins can interact (Wi j value −1). The
value of Wi j will be +1 if the interaction is not possible because one of the two genes
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is not expressed.
Wi j =

−1 if i expressed, j expressed
+1 if i or j not expressed
+1 if i not expressed, j not expressed
(3.1)
Consistent with the main idea of the algorithm, the local_nE is defined as the
sum of the energy from all the nodes connected to a given node i . This influence is
calculated by multiplying the expression of each gene (normalized value of expression,
S) by the associated weights of the connected nodes (Wi j ), as summarized in Equation
3.2.
local _nE(i )=−∑
j
Wi j ∗Si ∗S j (3.2)
According to the definition in Equation 3.2, the local_nE is maximal when Wi j ∗
Si ∗S j is at its minimum, representing active connections between nodes of expressed
genes (Equation 3.1, case 1) and indicating that any alteration in this node will desta-
bilize the network. The value of the local_nE decreases for those node connections
that involve at least one gene that is not expressed in that condition, reflecting the
fact that the interactions cannot take place (Equation 3.1, cases 2 and 3). In these
situations, the local_nE achieves its minimum values indicating network stability.
The local_nE function measures the stability of a single protein or node i in
function of its neighborhood, i.e., only with respect to the directly interacting partners,
and not within the entire network. The global nE value (Equation 3.3), and therefore
the stability of the entire network, will be a consequence of the equilibrium between
interactions among active (corresponding to the expressed genes) and inactive nodes
(corresponding to the non-expressed genes).
nE =∑
i
local _nE(i ) (3.3)
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3.4.5 Computation of network robustness
To assess the robustness of the system, we have analyzed how the network struc-
ture changes as nodes are removed in accordance with previously defined procedures
(Iyer et al., 2013). Changes in the network structure are evaluated in terms of the size
of the largest connected component of the network. Networks in which the largest
component decreases faster than that of the original network are considered to be less
robust to perturbations. Thus, nodes are removed in decreasing order of their local_nE
scores (Equation 3.2), removing the proteins (or nodes) with higher local_nE values
first (i.e., those with more active connections), and those with the lowest local_nE
scores last (i.e., those less connected to their neighbors).
Network robustness is measured through the R-index in Equation 3.4, where α
corresponds to the size of the largest connected component within the network after
a node is removed.
R = 1
N
N∑
i=1
α(i /N ) (3.4)
We have computed the R-index for cancer and normal control samples at each
step after the removal of nodes in function of the order of local_nE scores.
3.5 Results
Using this new approach, we have analyzed four gene expression datasets for
cancer (ovarian, colon, liver and kidney), four data sets for SCZ, and five for AD (Table
3.1) each having sufficient disease and control samples, and fulfilling our quality
control criteria (see Section 3.3.2). For each disease and data set, PPIN stability is
assessed in both the disease and control samples. In other words, we have simulated
a weighted interaction network for each sample, mapping S into the PPIN, directly
applying the proposed algorithm and obtaining a nE value. The distribution of the nE
values for the normal (N) and disease (C) conditions are then studied (Figure 3.3) and
a global nE is obtained for each disease.
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3.5.1 Increased neighbor-energy in cancer tissue
The cancer PPINs present characteristic instability, reflected by higher nE values
than their normal control samples (Figure 3.3a). A Mann-Whitney (Wilcoxon-rank)
test is used to evaluate whether the medians of a test variable differed significantly
between the normal and cancer samples, which proves to be the case for each tissue
(represented below the x-axis). The Wilcoxon Mann-Whitney test is a non-parametric
statistical test that computes the difference between the distributions of data col-
lected in two experimental conditions (control and cases in our case). It returns a
p-value, and values below than 0.05 indicate that the two distributions under study
are meaningfully different. Very significant Wilcoxon test p-values are obtained for the
ovarian, colon, liver, and kidney data sets (3.11e-04, 2.62e-03, 2.10e-05, and 2.33e-08,
respectively), indicative of meaningful and important differences between the nE
distributions in cancer and normal samples, with cancer samples being considerably
less stable than their normal counterparts.
In Figure 3.3a the boxplots representing cancer (in green) and normal control (in
yellow) nE values distributions are shown. Below, the Wilcoxon-rank p-value indicates
how significative the medians difference are between cancer (green) and control
normal (yellow) distributions.
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Figure 3.3: The nE distribution that maps all the genes in the PINA network in the:
(a) normal (N) and cancer (C) states (ovarian, colon, liver and kidney); (b) normal
(N) and AD (C); (c) normal (N) and SCZ disease (C) states. The Wilcoxon-rank p-
value is presented below the x-axis.
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3.5.2 Decreased neighbor-energy in tissues from CNS
disorders
Significant differences in nE distributions are evident when AD (C) and normal (N)
samples are compared (Figure 3.3b), and significant Wilcoxon p-values are obtained
for the nE distribution in virtually all of the AD studies. AD samples have smaller nE
values than the normal samples, reflecting increased stability (decreased instability)
in the AD network. By contrast, we only observe relevant differences between the
nE distributions of the normal and disease states for one of the four SCZ data sets
available (Figure 3.3c). This discrepancy between the different SCZ networks suggests
that further studies are required for this condition, and the underlying cause is unlikely
to be revealed until new, high quality experimental datasets become available.
In Figure 3.3b the boxplots representing AD (in green) and normal control (in
yellow) nE values distributions are shown. Below, the Wilcoxon-rank p-value indicates
how significative the medians difference are between AD (green) and control normal
(yellow) distributions. In the same way, Figure 3.3c shows the corresponding results
for schizophrenia-control cases.
Similar results are obtained when networks other than PINA networks are used,
including a smaller HPRD network and a larger HIPPIE one (see Appendix B). It is
important to clarify whether these differences are the product of general differences
in expression between cancer, normal and neurological disease tissues. However, the
normalized expression data (Figure 3.4) indicate that there is no difference between
the global levels of normalized expression in this study. This is, Figure 3.4 shows for
each disease the distributions of the gene expression data after being normalized. It
can be seen, looking at the horizontal line (Q2,median), that there are no significant
differences between each case(C)-control(N) gene expression distributions.
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Figure 3.4: Gene expression distribution in: (a) normal (N) and cancer (C) states
(ovarian, colon, liver, and kidney); (b) normal (N) and AD (C) conditions; and (c)
normal (N) and SCZ (C) conditions.
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3.5.3 Consistency of the results
In order to assess the consistency of the results we have analyzed sub-networks
obtained by randomly sampling the complete network. Accordingly, 86% of the sub-
networks containing 10% of the proteins of the original PINA network produce similar
results to the complete network. In other words, not only is there significant instability
in the overall network but most of the regions of the network conformed to this
behavior, with only a few of them behaving distinctly (Figure 3.5 which includes the
nE scores for the first one hundred random sub-samples).
For such aim, we have selected aleatory genes from the network, and normalized
the overall nE score to the total number of genes in the network. We have created
100 sub-networks with different sizes ranged from 1,000 to 1,500 proteins (Figure
3.5), yet similar results are obtained with random sub-sampled networks of 500 or
fewer proteins. The result we obtain with the whole network is not trivial but rather,
it appears to be quite significant. Figure 3.5 shows 100 nE distributions for normal
(N, in yellow) and cancer (C, in green) gene expression datasets, for which random
sub-networks (selecting 1,000-1,500 random proteins) have been created.
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Figure 3.5: The nE distribution mapping all the genes in 100 random sub-sample
networks in the normal (N) and cancer (C) conditions, sorted by increasing p-
values, from left to right and from the top to the bottom. In red, cells with non-
significant differences in the nE scores between the N and C conditions are shown,
representing 14% of the random sub-networks.
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3.5.4 Increased neighbor-energy in cancer evolution
To further study the network instability in cancer, we have assessed whether
tumor progression might be related with increased instability. For such objective, we
have searched gene expression datasets for data associated with different stages or
phases of cancer. Using two cancer datasets (colon and liver cancer) that contain
gene expression from different tumor stages (see Table 3.1) we have checked whether
network instability is affected by the progression of cancer (and so, as time evolves).
Figure 3.6 shows the nE distributions in different stages of the cancer. In Figure 3.6a
it can be seen that the median of the nE distribution increases with the level of the
liver cancer. The first boxplot corresponds with the normal phase, and the next boxes
match with very early hepatocellular carcinoma (HCC), early HCC, cirrhosis with HCC,
and advanced HCC (crescent order in disease). A similar outcome is observed in the
colon cancer evolution (Figure 3.6b). The median of the nE distributions increases
while the stages are worse in the cancer development. Hence, the initial results show
a significant increase in network instability when the datasets obtained at different
stages of tumor progression are compared
normal eHCCveHCC cirr_aHCC aHCC
n
E
a b
n
E
stage I stage II stage III stage IV
Figure 3.6: The nE distributions mapping all the genes at: (a) evolving stages of hep-
atocellular carcinoma (HCC): normal, very early HCC (veHCC), early HCC (eHCC),
cirrhosis with HCC (cirr_aHCC) and advanced HCC (aHCC); and (b) progressive
stages of colon cancer stages I, II, III, and IV.
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3.5.5 Network stability towards perturbations
Stability has previously been described as a relatively invariant network state when
perturbations are introduced. Thus, it is necessary to perform additional experiments
to show that our definition of network stability measured through the nE score corre-
lates well with this classical definition of robustness. Removing nodes from a network
and then studying the evolution of the network’s connectivity provides a natural model
to study the robustness of networked systems (Callaway et al., 2000; Cohen et al., 2000;
Iyer et al., 2013). Changes in the network structure are evaluated in term of the size
of the largest connected component of the network. Networks in which the largest
component decreases faster than that of the original network are considered to be
less robust to perturbations. Thus, nodes have been removed in decreasing order
of their local_nE scores (Equation 3.2), and accordingly the proteins (or nodes) with
higher local_nE values (i.e., with more active connections) have been removed first,
and proteins with the lowest local_nE scores (i.e., less connected with their neighbors)
have been removed last. Accordingly, network robustness has been measured by the
R− i ndex in Equation 3.4, where α corresponds to the size of the largest connected
component within the network after a node is removed. In this manner, the R−i ndex
can be used to quantify network robustness (see Section 3.4.5).
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Figure 3.7: Perturbation robustness against local_nE sorted score in: (a) cancer
samples (red) and normal controls (blue); and in (b) AD samples (red) and normal
controls (blue).
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The successive removal of nodes according to their local_nE score produces a
significant difference between the perturbation robustness in cancer and normal
samples (Figure 3.7a), and in AD and normal samples (Figure 3.7b). When nodes are
removed in a descending order of local_nE scores, greater robustness is evident in
normal control networks (R-index = 0.52) than in cancer networks (R-index = 0.33:
Figure 3.7a). By contrast, AD networks are more robust (R-index = 0.50) than their
corresponding normal control networks (R-index = 0.39: Figure 3.7b). Hence, the
definition of the nE score appears to be closely associated to network stability and as
such, with the network’s robustness to perturbation.
3.5.6 Decreased instability in biological pathways implicated in
Alzheimer’s disease
We have analyzed the decreased network instability observed for AD samples in
more detail and in particular, we have investigated the possible role of the proteins
implicated in vesicle trafficking at synapses. Communication between neurons is
mediated by the release of neurotransmitter from SVs and the expression of a group of
genes involved in SV trafficking is reduced in brain tissues from AD cases. Indeed, the
loss of synapses has been correlated with cognitive decline in AD and a malfunction
of SV trafficking could be implicated in disrupting neuronal circuits in AD (Yao et al.,
2003).
Figure 3.8: The nE distribution mapping all the genes in the normal (N) and disease
(C) states in AD into the sub-network created from proteins involved in the synaptic
vesicle cycle. The Wilcoxon-rank p-value is indicated below the x-axis.
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As for the complete PPIN, there is a consistent decrease in instability in the SV
related sub-network of proteins from AD samples (Figure 3.8). The difference in
the nE score suggests that important hubs within the network are expressed and
regulated in opposite directions in AD and normal samples. Indeed, nine genes
related to endocytosis are expressed in opposite manners in normal and AD samples:
KIT, CLTA, CLTB, AP2M1, AP2S1, AP2B1, HLA-B1, AP2A2, and RAB11FIB2. Three
genes associated with SV trafficking (SYP, STX1A and UNC13B) are inversely expressed
in both conditions and they are highly connected in the protein network (hubs).
In particular STX1A (syntaxin 1A) is known to regulate the exocytosis of SVs and
neurotransmitter release (Bennett and Scheller, 1993; Greengard et al., 1993; Hosaka
et al., 1999). There is a clear trend towards reduced STX1A expression in all AD
samples, which has a lower nE score than in normal control samples. Indeed, when
the STX1A gene is not expressed (in blue) nor are its neighbors and conversely, when
the STX1A gene is expressed (in red) so are most of its neighbors (Figures 3.9 and 3.10).
Accordingly, the stability of a particular sub-network relevant to a neurological disease
under study is affected in the same way as the stability of the entire network.
The following figures (Figures 3.9 and 3.10) represent PPI sub-networks created
from proteins that are involved in the SV cycle in the disease and normal states for AD
respectively. Blue nodes represent non-expressed gene products, red nodes expressed
gene products, red edges represent interactions between proteins in which both genes
are expressed and gray edges represent other combinations. The red clouds contain
the STX1A protein as well as all of its interacting partners
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Figure 3.9: Network study of a particular pathway associated with the synaptic
vesicle cycle - disease case.
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Figure 3.10: Network study of a particular pathway associated with the synaptic
vesicle cycle - normal case.
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3.6 Discussion
We have designed an approach inspired on DSA, representing PPINs as systems of
nodes that are dynamically updated towards a global state of stability. Our strategy is
based on the definition of a neighbor-energy function that measures the stability of the
network in the general deterministic approach, where nE indicates network stability,
and it can be interpreted in terms of resistance to alterations and perturbations. In
this study, we have analyzed a large set of experimental data on gene expression and
various PPINs.
The first significant finding of this study is that networks containing information
about expression in four human cancers (ovarian, colon, kidney, and liver) are less
stable than the control networks of normal samples. Moreover, this instability in the
network seems to increase as these cancers evolve, at least in the tumor progression
data sets analyzed. The approach employed is based on the analyses of samples in
different conditions and it does not include temporal evolution per se. Thus, the
results obtained by analyzing the temporal progression of tumors can be taken as an
indication of network evolution towards a less stable state and a way of reconciling
our methodology with the standard SA applications.
The randomness or disorder in the local flux distribution surrounding any given
node in the network i has been quantified (West et al., 2012), showing that cancer
is characterized by an increase in network entropy. This observation could be con-
sidered as independent confirmation of our general conclusion. Indeed, when gene
expression data is previously integrated with a PPIN for six cancer tissues (Teschen-
dorff and Severini, 2010), an increase in network entropy is again seen to be associated
to cancer based on a fluctuation theorem of dynamic systems theory. At the bio-
logical level cancer has been associated with a general destabilization of cellular
processes related to the organization of the genome, its replication and repair (Murga
and Fernández-Capetillo, 2007). A conceptual framework explains how mutations
in genes that control genetic stability are selected during tumor progression (Ne-
grini et al., 2010; Loeb, 2011; Wadhwa et al., 2013; Solé et al., 2014). Therefore, our
observation of network instability in cancers fits well with current ideas in this field.
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Technically, our approach offers important advantages. First, raw gene expression
data sets are divergent and independent, which represents an important difference.
Additionally, we use a high quality filtered and curated PPIN, which while having
practically the same number of total nodes it is less connected than those used in
earlier studies. To deal with our biological problem we need to consider both the state
of the nodes as well as the strength of the connections between them. This is possible
with methods where these two important issues are considered, such as DSA, one of
the generic means to resolve the optimization problem (S. Kirkpatrick et al., 1983).
Our second important finding is that the AD network is more stable than its
control normal network, with a significant increase in the nE of the corresponding
networks. This is an interesting behavior that contrasts with that of cancers, and
as far as we know is detected here for the first time. One possible interpretation
of these results would be that cancer implies a general deregulation of cell growth
through the hyperactivation of certain pathways, resulting in a destabilization of their
interactions, while AD and other neurological disorders imply the stabilization of
biological processes and network interactions, and their general slowing down. The
striking contrast in the behavior of cancer and AD networks, from less to more stable
networks, should be considered in the context of the observed inverse comorbidity of
these two groups of diseases. A substantial number of epidemiological studies have
shown that there is an inverse relationship between cancer and several central nervous
system diseases, including AD. In other words, patients with AD tend to less frequently
suffer some types of cancer (Tabarés-Seisdedos et al., 2011; Tabarés-seisdedos and
Rubenstein, 2013) [for a complete meta-study of the available epidemiological studies
see (Catalá-López et al., 2013)].
Finally, given the importance of the diseases discussed in this work, it is neces-
sary to make these results accessible for future experimental analysis. In this sense,
an initial study of the molecular basis of this inverse comorbidity identified sets of
genes expressed weakly in AD and strongly in cancers (Ibáñez et al., 2014). The new
methodological approach developed here represents a further advance with respect
to that initial approximation, where genes are not considered as independent units
but rather as part of a connected network. This approach could be used as a classifier
to distinguish cancer and normal samples. Another possibility will be to cluster the
results of this procedure in order to extract specific proteins for which additional ex-
perimental information could be available, or could be tracked in direct experiments.
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Furthermore, this scheme could be also applied to any network system where the
elements are characterized by a state Si and their interactions associated to a weight
Wi j . In a biological context there are numerous systems with these characteristics,
such as protein interaction and gene control networks. In the future, the application
of clustering techniques to disease networks, such as self organizing maps (SOM), will
render information not on single genes but on clusters of collaborating genes, mov-
ing towards the study of the molecular causes of comorbidity to the level of systems
biology.
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CNS disorders related proteins
4.1 Summary
A pattern recognition system is presented, in which proteins related with CNS
disorders and cancer related proteins are classified. We have defined two attributes
that are capable to categorize in different groups the majority of the proteins related
to cancer or CNS disorders, corresponding with clusters with high or low feature
values. The dex feature is indicative of the number of neighbors of each protein being
expressed, important to estimate how connected and active proteins are within the
PPIN. We have adopted the local_nE attribute from the work presented in chapter
3 and published in (2015), which measures the stability of a single protein in its
neighborhood.
4.2 Introduction
The development of large-scale genomics methods and large biological databases
in combination with different statistical approaches and adequate machine learning
techniques build the basis for the analysis of the relations between human complex
disorders. For instance, integrating multiple ’omics’ analyses in combination with a
genetic algorithm (Liu et al., 2013b) identifies essential biomarkers in preeclampsia,
a bioinformatics-based drug approach is capable of repurposing already approved
drugs and identifying novel class of molecules to treat diseases (Jahchan et al., 2013)
or combining gene expression and single nucleotide polymorphisms successes re-
covering, and predicting known therapeutic targets across several human diseases
through a systematic approach (Fan-Minogue et al., 2015).
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Gene expression determines whether the gene is expressed or not. Most genes
code for proteins that are the ones carrying out most biological processes. Many
protein functions take place in the context of the interactions with other proteins,
which are described in the PPIN, in which each node represents a protein and the
edges the interactions with other proteins. It is not possible to obtain a network
for each condition (disease or normal), and thus, an alternative is to combine gene
expression data with PPIN to gain a better understanding of the organization and
level of activity of the network (Srihari et al., 2014; de Baumont et al., 2015; Chen
et al., 2015; Xiao et al., 2015). The strategy of combining PPINs with gene expression is
artificial, since the networks that are available correspond to a particular state rather
than diseases, individuals or conditions. Numerous studies have used PPIs and gene
expression information to study complex disorders (Chuang et al., 2007; Pujana et al.,
2007; Hudson et al., 2009; Milanesi et al., 2009; Komurov et al., 2010; Schramm et al.,
2010; Teschendorff and Severini, 2010; West et al., 2012; van Pel et al., 2013), and
investigated the properties of the corresponding networks (Schadt, 2009).
The recent development of more comprehensive and accurate PPINs provides ad-
ditional possibilities in this area (Cusick et al., 2009; Barabási et al., 2011; Kerrien et al.,
2012; Licata et al., 2012; Chatr-Aryamontri et al., 2013; Rolland et al., 2014). Protein
interaction maps have been used to study the molecular organization of cellular sys-
tems and the perturbations created by disease (Dobson et al., 2014; Safari-Alighiarloo
et al., 2014). In particular, topological analyses of PPINs show that cancer proteins
tend to be central within the network as they are highly connected (Jonsson and Bates,
2006; Taylor et al., 2009; Sun and Zhao, 2010; Xia et al., 2011; Choura and Rebaï, 2012;
Xiong et al., 2014). It has been proposed that important proteins for a cell’s survival
are highly connected (Jeong et al., 2001) and altering them has profound effects on the
interaction network. Similarly, studies on the genomic and network characteristics
of genes that mutated in cancer indicate that these genes tend to encode central
hubs within a PPIN (Rambaldi et al., 2008). Correspondingly, Xia et al. (2011) argued
that cancer-related proteins (CRPs) have a much stronger protein–protein interaction
density than control proteins in the whole human interactome. The authors retrieved
cancer and non-cancer essential genes from different repositories and studied the
different topological features within the PPIN, such as the degree, betweenness, and
centrality measures. In this study, we examine critically this hypothesis by comparing
the network organization of proteins directly related with two different disease groups
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(cancer related proteins CRPs and proteins related with neurological disorders - NRPs).
It is particularly interesting to examine the two groups of diseases given the active
debate on the medical and biological relations between cancer and neurological or
CNS disorders.
At the medical level, population and epidemiological studies have shown that
some types of cancers and CNS disorders co-occur less often than expected. In-
deed, patients with certain neurological disorders, including those suffering from
Parkinson’s or Alzheimer’s disease, have a lower than expected tendency to develop
some forms of cancer (Behrens et al., 2009; Tabarés-Seisdedos et al., 2011; Behrens
et al., 2012; Tabarés-Seisdedos and Rubenstein, 2013). A phenomenon called inverse
comorbidity.
At the molecular level, we detected a common set of genes and biological path-
ways which expression levels are regulated in opposite directions in CNS disorders
and cancer [described in chapter 2 and published in (Ibáñez et al., 2014)]. Later
using a simulated annealing inspired approach, we showed that CNS disorders are
characterized by lower network instability while networks informed with cancer gene
expression data tend to have higher instability (Ibáñez et al., 2015). Our interpretation
is that the larger number of interactions among CRPs makes the network more sus-
ceptible to destabilization. Similarly, West et al. (2012) and Teschendorff et al. (2010)
found that cancer cases have an increased network entropy using a different com-
putational approach. This study aims to clarify the origin of the differential network
behavior of CRP and NRPs, by studying their network neighborhoods with different
clustering methodologies. Clustering is an elemental problem with many applications
in biology, medical research, bioinformatics, and other disciplines. Particularly, self-
organizing maps (SOM) have been used to recognize and classify features in human
hematopoietic gene expression data. A hierarchical clustering in the budding yeast
Saccharomyces cerevisiae was proposed (Eisen et al., 1998) in which clustering gene
expression data efficiently grouped together genes of known similar function. Graph
theoretic approaches, among others, were also used to group together genes of known
similar function or genes with particular features (Yeung et al., 2001; Ben-Dor et al.,
2004).
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4.3 Material
4.3.1 Microarray gene expression data
Gene expression experimental raw data (CEL files) have been downloaded from
the Barcode human transcriptome repository (bar) for ovarian, colon, and liver cancer
samples. For the CNS disorders, diseased samples have been downloaded from the
NCBI GEO omnibus (geo) and the Stanley Medical Research Institute Online Genomics
Database (smr) for schizophrenia (SCZ), Alzheimer’s disease (AD), and Parkinson’s
disease (PD) (see Table 4.1).
Each CEL file includes probe intensities information produced at the end of the
microarray scan, and this data must be preprocessed (see Section 4.4.1). Table 4.1
incorporates the experimental gene expression datasets used. The tissue field indi-
cates the human region in which the experiment is done, the platform type the official
name of the microarray platform used, the sample size the total number of patients
included (control and cases), and the source the identifier of the gene expression
dataset in the original repository.
Table 4.1: Gene expression datasets.
Tissue Platform
Sample
Size
Source
Alzheimer’s disease
Entorhinal Cortex HG-U133Plus2 23 GSE5281
Hippocampus HG-U133Plus2 23 GSE5281
Medial Temp. Gyrus HG-U133Plus2 28 GSE5281
Posterior Singulate HG-U133Plus2 22 GSE5281
Primary Visual Cortex HG-U133Plus2 31 GSE5281
Superior Frontal Gyrus HG-U133Plus2 34 GSE5281
Hippocampus HG-U133Plus2 24 GSE1297
Schizophrenia
Postmortem cerebellum HG-U133Plus2 28 GSE4036
Postmortem frontalBA46
cortice
HG-U133Plus2 55 Dobrin
Postmortem hippocampus
(CA1)
HG-U133Plus2 41 Laeng
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Table 4.1 – Gene Expression datasets
Tissue Platform
Sample
Size
Source
Postmortem thalamus (MD) HG-U133Plus2 26 Kemether
Parkinson’s disease
Postmortem thalamus HG-U133Plus2 26 GSE7621
Postmortem medial, lateral
and frontal
HG-U133A 45 GSE8397
Substantia nigra HG-U133A 29 GSE20292
Colorectal cancer
Colon tissue HG-U133Plus2 33
GSE4183
GSE7307 (GSM175905)
GSE2109
Ovarian cancer
Ovary tissue HG-U133Plus2 278
GSE9891
GSE2109
GSE9890
GSE3526
GSE7307
Liver cancer
Liver tissue HG-U133Plus2 129
GSE6222
GSE9829
GSE9843
GSE6956
GSE11045
GSE7307
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4.3.2 The protein–protein interaction network
We have used the human protein interaction network from the Protein Interaction
Network Analysis (PINA) database. PINA (pin) is an integrated platform of PPI data
extracted from six different public databases: IntAct, MINT, BioGRID, DIP, HPRD, and
MIPS/MPact. It includes self-interactions, interactions predicted by computational
methods, and interactions between human proteins and proteins from other species.
For our purpose, we first have used data from the PINA website (pin) and then filtered
the data by requiring PPIs to have experimental evidence and removing redundancy
and self-interactions as well as interactions involving proteins not from Homo sapiens.
We only have considered the interactions among proteins that were also detected in
the microarray platforms (Figure 4.2b). The resulting filtered PINA network consists
of 10,650 proteins with 63,119 interactions. Each node denotes a protein encoded by
a gene, and each edge denotes an interaction existing between two proteins. PINA
has also been used in recent studies, including those of Xia et al. (2011) and Laakso et
al. (2010) among others.
It is important to emphasize the dimension and complexity of the data. For each
disease, different experimental gene expression datasets are retrieved (biological
replicates) with cases and control samples. Each sample includes 10,650 genes. Ac-
cordingly, we are working with 875 samples containing each of one 10,650 genes.
4.4 Methods
We have designed a pattern recognition system using a SOM clustering method-
ology, and we have validated further with K-Means. The corresponding flow chart
is presented in Figure 4.1. In the first step, preprocessing each individual microar-
ray is necessary to estimate the expression level of each gene on the array (Section
4.4.1). Defining the features that the clustering method classifies into different kinds
of groups or clusters is fundamental (Section 4.4.2). Thus, we have defined dex and a
local_nE (defined below), this last attribute is based on our previous study (Ibáñez
et al., 2015), as the principal characteristics of each gene to be classified. To do this,
we have normalized all the data (Section 4.4.3), and analyzed the optimal number of
clusters (Section 4.4.4) in which the genes are more effectively grouped (Section 4.4.5).
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A SOM clustering algorithm is developed on the space of dex and local_nE for every
gene in the cancer and neurological samples (Section 4.4.4). This step is validated with
the K-Means approach. Finally, we examine each cluster independently by analyzing
which groups with higher local_nE and dex values are more enriched in the CRPs than
in the NRPs, and vice versa.
Data discretization
Estimation of the optimal
number of clusters
SOM
K-Means
Percentage of CRPs
and NRPs
Biological
enrichment analysis
Feature definition
Microarray gene
expression
preprocessing
Step 1
Step 2
Step 3
Step 4
Step 5
Figure 4.1: Flow chart of our pattern recognition system.
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4.4.1 Microarray gene expression preprocessing (Step 1)
The preprocessing of each single microarray sample is an essential step to es-
timate the expression of each gene on the array. The SCZ, AD, and PD samples in
the CNS disorders and the ovarian, colon, and liver cancer samples are normalized
using frozen Robust Multiarray Analysis (fRMA) (McCall et al., 2012) from the R affy
package (Gautier et al., 2004). The fRMA processes each array individually and ac-
counts for probe variability, batch effects, probe effects, array-to-array variability, and
background noise, obtaining background-corrected gene-level intensities. Afterwards,
the methodology proposed by (Zilliox and Irizarry, 2007) have been used to map the
gene intensities (Z-score) into a vector of ones and zeros that denote which genes
are expressed (ones) and unexpressed (zeros) for each sample (Figure 4.2a). To com-
pare the Z-score among all the diseases, we have processed it following the strategy
described at section 3.4.3.
In summary, two different data types are obtained for each sample: the significance
level (Z-Score) of the gene being expressed or not, and the information on whether
the gene is expressed (one) or not (zero) (Figure 4.2a).
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Figure 4.2: (a) Subset of the preprocessed and normalized gene expression data. (b)
Subset of the filtered PPIN. (c) Subset of the dex and local_nE values for each gene.
(d) Example of the BRCA1 local_nE computation in a subnetwork.
99
Chapter 4. Recognition between cancer and CNS disorders related proteins
4.4.2 Feature selection (Step 2)
The selection of features is essential when a classification algorithm is used. The
number of features involved in the analysis directly affects the performance and
robustness of the methodology (Jain and Chandrasekaran, 1982).
For each protein in the PPIN, the dex and local_nE attributes are defined. The
dex feature indicates the degree of each protein "expressed" in the PPIN, that is, the
number of neighbors of each protein being expressed. This feature is important to
estimate how connected and active a protein is within the network. The degree of
proteins is an invariable attribute in the PPIN. For the local_nE attribute, we adopt
the nE function (Ibáñez et al., 2015) described in chapter 3. The original nE function
measures the stability of an entire network. Stability describes a network state that is
not significantly altered when its properties or the perturbations within it are changed.
In this new study, we take advantage of the local_nE function, which measures the
stability of a single protein in its neighborhood, that is, only with the direct interacting
partners, and not in the entire network as in the original work (Ibáñez et al., 2015).
Our principal objective is to determine the stability of each protein with its neighbors,
rather than within the whole network. To make our goal more precise, the definition of
local_nE is fundamental to determine the effect and alterations a protein can produce
in its neighborhood.
The system is represented by a PPIN, and nodes (Si ) represent the proteins as-
sociated with the value of expression of the corresponding gene. Each Si describes
the significance level of the gene i being expressed or not. Edges (Wi j ) show the
existing interactions among proteins, and are defined in Equation 4.1. This equation
is equivalent to 3.1, but it is shown here again for better reading.
Wi j =

−1 if i and j are expressed
+1 if i or j are not expressed
+1 if i and j are not expressed
(4.1)
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Following the main idea of the deterministic simulated annealing algorithm, the
local_nE function defined (Ibáñez et al., 2015) is the sum of the energy of all nodes
connected to a given node i . These influences are calculated by multiplying the
level of expression of each node (Si ) by the associated weights, with all the nodes
interconnected with the first one (Wi j ), as expressed in Equation 4.2. This equation is
equivalent to 3.2, but it is shown again here for better reading.
local _nE(i )=−∑
j
Wi j ∗Si ∗S j (4.2)
According to the definition in Equation 4.2, local_nE is maximal when Wi j ∗Si ∗S j
is at its minimum. It represents the active connections among the nodes of the
expressed genes (Equation 4.1, case 1) and indicates that any alteration in this node
will destabilize the network. The value of local_nE decreases for node connections
that involve at least one gene that is not expressed in that condition, thus indicating
the fact that the interactions cannot take place (Equation 4.1, cases 2 and 3). In this
situation, the local_nE achieves its minimum value, thus indicating network stability.
Consequently, the local_nE function measures the stability of a single protein
or node in the function of its neighborhood, that is, only with the direct interacting
partners and not in the entire network.
4.4.3 Data discretization (Step 3)
The SOM and K-Means algorithms we adapt here use the Euclidean distance to
measure the distance between a data element (protein) and its cluster’s centroid. In
using the Euclidean distance, the clustering results can be greatly affected by the
difference in scale of the dimension from which the distances are computed. There-
fore, as these distances are computed from processed raw data, they are normalized
to prevent dependence on the choice of measurement units (Han et al., 2011). The
possibility that scores with the largest range could dominate the distance computation
is avoided. In this manner, local_nE and dex features are normalized so that each
feature has mean 0 and variance 1. For such aim, the nor mali ze function of the som
R package (som) is used. This function normalizes the data so that each column has
101
Chapter 4. Recognition between cancer and CNS disorders related proteins
mean 0 and variance 1 (each column represents each feature).
4.4.4 Determination of the optimum number of clusters (Step 4)
The number of clusters is initially unknown. No predefined classes exist before
grouping, and finding an appropriate metric for measuring whether the found cluster
configuration is acceptable or not is a difficult task. Therefore, an evaluation of the
clustering methodology is necessary (Legány et al., 2006). Several validity indices
are here tested, and similar results are obtained using Calinski-Harabasz (C Hi ndex)
(Calinski and Harabasz, 1974) and Davies-Bouldin (DBi ndex) (Davies and Bouldin,
1979) validity indices. The R fpc package (fpc) and R clusterSim package (clu) are used
for the two validity indices, respectively, to test the outcome of each index for different
numbers of clusters.
The idea behind the CH measure (Calinski and Harabasz, 1974) is to compute
the sum of the distances between the k-th cluster and the other k −1 clusters, and
to compare this sum with the internal sum of the distances for the k clusters. This
measure is one of inter-cluster (dis)similarity over intra-cluster (dis)similarity. It works
as shown in equation 4.3:
C H(k)= B(k)/(k−1)
W (k)/N −k (4.3)
where B(k) is the distance among clusters, W (k) is the distance in the cluster, k is
the index of the cluster, and N is the total amount of clusters.
A good clustering is associated with the highest CH value, and it occurs when the
difference among the clusters is high, and the within cluster difference is low. The
main goal of this step is to predict the optimal number of groups in which data can
be organized according to the defined attributes. Accordingly, C Hi ndex is used for
measuring the "goodness" of the clustering without the need for a manual exploration
step (a similar result is obtained with DBi ndex).
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4.4.5 SOM and K-Means clustering (Step 5)
In the current study, SOM and K-Means clustering algorithms are developed on the
space of dex and local_nE attributes for every gene in the samples. Clustering solutions
are gathered for a pre-specified number of groups, and the solution maximizing
C Hi ndex (Calinski and Harabasz, 1974) is selected.
A clustering problem consists of elements and a feature vector for each element.
A measure of similarity is defined between pairs of such vectors. In our study, the
elements correspond with the encoded proteins, and the vector of each protein con-
tains local_nE and dex values. The main goal is to partition the elements into subsets
(i.e., clusters) to satisfy the two criteria defined in (Shamir and Sharan, 2002): homo-
geneity (elements in the same cluster are highly similar to each other), and separation
(elements from different clusters have low similarity to each other).
These classical clustering algorithms, which assume an already known number of
clusters, have been widely used in several works (Thalamuthu et al., 2006; de Castro
Leão et al., 2009; Omer et al., 2014). The main goal is to minimize the distance among
elements and the centroids of their assigned clusters (Shamir and Sharan, 2002). Let
M be the n∗m matrix. For a partition P , the elements in {1, ..., } are denoted by P (i ),
which is the cluster assigned to i , and by c( j ), which is the centroid of cluster j . Let
d(v1, v2) denote the Euclidean distance between the vectors v1 and v2. K-Means
attempts to find a partition P in which the error function Ep =∑Ni=1 d(i ,c(P (i ))) is
minimum.
The current partition is modified by checking all possible modifications of the
solution, in which one element is moved to another cluster, and by making a switch
that reduces the error function. SOMbrero R package (Olteanu et al., 2012; Bendhaiba
et al., 2015; Olteanu and Villa-Vialaneix, 2015) and stats R package (sta) are used for
SOM and K-Means clustering respectively.
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4.5 Results
The pipeline proposed in section 4.4 is followed (Figure 4.1) for result analysis and
interpretation. Microarray raw data are preprocessed in the first term; the features
for the clustering are defined; the optimal number of clusters is determined; both the
SOM and K-Means clustering algorithms are conducted; and the cluster results are
biologically interpreted.
The SOM and K-Means clustering algorithms are applied on the space of dex and
local_nE features for every gene in the cancer and neurological disorder samples with
similar outcomes. The optimal number of groups is defined by maximizing C Hi ndex
(Calinski and Harabasz, 1974) (a similar outcome is obtained by minimizing DBi ndex ),
as described in section 4.4.4.
4.5.1 Outcome of the feature selection
Considering dex and local_nE features independently, we do not observe differ-
entiated groups when these two feature values in the genes expressed in cancer (in
red) and CNS disorders (in blue) are represented (Figure 4.3a and 4.3b). However,
when both dex and local_nE values are combined in genes expressed in cancer (in red)
and CNS disorders (in blue), two groups are distinguished with differentiate patterns
(Figure 4.3c).
To estimate how adequate these defined features are, we have used different
classifiers such as Weka (Mark Hall, Eibe Frank, Geoffrey Holmes, Bernhard Pfahringer,
Peter Reutemann, 2009) for Random Tree Forest, J48, and Bayes classifiers with and
without stratification. Consequently, genes from the cancer data are labeled “cancer”
and those from CNS disorders are labeled “neuro.” Considering dex and local_nE
values the previous classifiers are used to correlate genes according to each feature
value to each class ("cancer" or "neuro"). The percentages of genes correctly matched
are 98.3%, 85. 7%, and 83.3% using Random Tree Forest, J48, and Bayes classifiers,
respectively (Figure 4.3d).
104
4.5. Results
d
e
x
p
a
rt
ia
l_
n
e
d
e
x
partial_negenes
genes
J48
Bayes
Correctly 
classified
instances
Percentage
Correctly Classified
1524 26 98,32%
85,74%2211329
1292 258 83,35%
Incorrectly 
classified
instances
Random 
Forest
a
b
c
d
0         200        400       600       800     1000     1200
0         200        400       600       800     1000     1200
0                 50                100               150              200
0
  
  
  
  
  
  
  
 1
0
0
  
  
  
  
  
  
  
2
0
0
  
  
  
  
  
  
  
3
0
0
0
  
  
  
  
  
  
  
 5
0
  
  
  
  
  
  
  
1
0
0
  
  
  
  
  
  
1
5
0
  
  
  
  
  
  
 2
0
0
0
  
  
  
  
  
  
  
 1
0
0
  
  
  
  
  
  
  
 2
0
0
  
  
  
  
  
  
  
3
0
0
Figure 4.3: Outcome of the feature selection (a) Representation of the dex value
in genes expressed in cancer (red) and CNS disorders (blue). (b) Representation
of the local_nE value in genes expressed in cancer (red) and CNS disorders (blue).
(c) Representation of both dex and local_nE values after normalization in genes
expressed in cancer (red) and CNS disorders (blue). (d) Outcome of the Random
Tree Forest, J48, and Bayes classifier algorithms considering both dex and local_nE
features.
4.5.2 Optimal number of clusters
The main goal here is to find out the most appropriate configuration of SOM and
K-Means in order to represent the topology of the data (see Section 4.4.4). Thirteen
K-Means and SOMs of different dimensions with the same data set are trained and
clustered, and validation indexes are computed for each configuration. The maximal
C Hi ndex , reflecting the "goodness" of the clustering, corresponds with 10 (Figure 4.4)
(similar result is obtained with DBi ndex). Consequently the K-Means and SOM are
going to be divided into 10 different groups (matrix with dimension 2x5).
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Figure 4.4: Estimation of the optimal number of clusters maximizing C Hi ndex .
4.5.3 SOM and K-Means approaches
Following the iterative process of the proposed pipeline, once the optimal number
of groups is estimated, both the SOM and K-Means clustering algorithms are per-
formed with similar outcomes. Proteins with a similar number of expressed neighbors
and having an approximate local_nE are sorted in the same cluster.
The number of proteins associated with cancer and CNS disorders is the same;
that is, we analyze the same proteins in all the diseases. If the clusters were generated
randomly, the elements inside each group would be adjusted as a binomial distri-
bution, Bi n(n,0.5), where n is the cluster size, and 0.5 is the probability of having a
cancer or neurological protein in a group. The binomial p-value is computed based
on the number of CRP or NRPs compared to the total amount of proteins within each
group. Accordingly, low binomial scores (p-value < 0.01) indicate that the proteins
within the cluster do not follow a binomial distribution, and so, the presence of CRP
or NRPs is significant.
Clearly separated groups are represented by different colors in SOM and K-Means
methodologies (Figures 4.5a and 4.6a). In Figures 4.5a and 4.6a are represented the
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proteins by their corresponding dex and local_nE values after the SOM and K-Means
respectively. In Figures 4.5b and 4.6b, each fraction in the pie chart symbolizes the
number of proteins related to each disease (AD, SCZ, PD, ovarian, liver, or colon can-
cer) with the feature values of the corresponding cluster, the p-value score associated
with the binomial distribution, and the total number of proteins in each cluster (n).
In Tables 4.2 and 4.3 the percentages of CRP and NRP for each cluster are repre-
sented.
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Figure 4.5: SOM clustering analysis (a) Proteins by their corresponding dex and
local_nE scores after SOM clusterization. (b) Pie charts containing the colored
fraction of diseases in each cluster characterized by proteins with similar local_nE
and dex values.
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Table 4.2: Percentage of proteins in each cluster associated with CNS disorders and
cancer with SOM.
Cluster
NRP
percentage (%)
CRP
percentage (%)
Cluster 1 29.5 70.5
Cluster 2 25.7 74.3
Cluster 3 32.6 67.4
Cluster 4 33.4 66.6
Cluster 5 33.4 66.6
Cluster 6 43.5 56.5
Cluster 7 54.2 45.8
Cluster 8 46.5 53.5
Cluster 9 66.6 33.3
Cluster 10 70.7 29.3
n = 544
binomial p-value = 2.7e-03 
n = 178
binomial p-value =  1.5e-03
n = 172
binomial p-value = 1.1e-04 
n = 20
binomial p-value = 1.9e-13
n = 3547
binomial p-value = 0.007 
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Figure 4.6: K-Means clustering analysis (a) Proteins by their corresponding dex and
local_nE scores after K-Means clusterization. (b) Pie charts containing the colored
fraction of diseases in each cluster characterized by proteins with similar local_nE
and dex values.
108
4.5. Results
Table 4.3: Percentage of proteins in each cluster associated with CNS disorders and
cancer with K-Means.
Cluster
NRP
percentage (%)
CRP
percentage (%)
Cluster 1 38.7 61.3
Cluster 2 31.9 68.1
Cluster 3 36.2 63.8
Cluster 4 27.5 72.5
Cluster 5 36.0 64.0
Cluster 6 27.9 72.1
Cluster 7 63.4 36.6
Cluster 8 10.0 90.0
Cluster 9 33.2 66.8
Cluster 10 31.7 68.3
2.4.3.1 Relevant clusters enriched in the CRPs that analyze very connected
proteins
Interestingly, groups with high dex and local_nE values [clusters 1 and 2 with
2.3e-05 and 5.5e-07 binomial p-values respectively in SOM (Figure 4.5) and clusters 4,
5, 6, and 8 with 1.5e-03, 1.5e-19, 1.1e-04, and 1.9e-13 binomial p-value respectively
in K-Means (Figure 4.6)] are enriched in CRPs (see Figure 4.5b and 4.6b). Tables 4.2
and 4.3 contain the percentages of CRP and NRPs within each cluster with SOM and
K-Means strategies accordingly.
To further validate this observation associated with CRPs, we have studied how
proteins are classified considering cancer cases and normal controls. In consequence,
protein distribution in cancer and normal control cases are also analyzed on the
space of dex and local_nE features (Figure 4.7). In the same direction, groups with
the highest local_nE and dex values are significantly enriched on CRPs (clusters 1, 3,
7, and 10 with 5.3e-23, 1.1e-12, 5.9e-23, and 3.5e-14 binomial p-values respectively).
Differently, clusters 6 and 9 are enriched on normal related proteins with 7.8e-29 and
7.8e-31 binomial p-value mutually.
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Figure 4.7: K-Means clustering analysis in cancer and normal control proteins (a)
Representation of the proteins by their corresponding dex and local_nE scores after
K-Means clusterization. (b) Pie charts containing the colored fraction of diseases in
each cluster characterized by proteins with similar local_nE and dex values. Each
fraction in the pie chart symbolizes the number of proteins in each disease with the
feature values of the corresponding cluster. The n parameter represents the number
of proteins in each cluster, and the p-value is the associated score with a binomial
distribution.
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2.4.3.2 Relevant clusters enriched in the NRPs that analyze less connected proteins
Conversely, groups with lower dex and local_nE values [clusters 7, 9 and 10 with
0.06, 2.3e-04 and 9.8e-06 binomial p-values respectively in SOM (Figure 4.5), and
cluster 7 with 0.02 binomial p-value in K-Means (Figure 4.6)] are enriched in the
NRPs (Table 4.2 and 4.3 specifically). In addition, these clusters correspond to the
largest groups, containing almost half of the total amount of proteins included in the
study. In particular, K-Means cluster 7 (Figure 4.6) is the one with the lowest dex and
local_nE values, and it is significantly enriched in the NRPs, with the 63,4% of the
proteins associated with a CNS disorder. Furthermore, cluster 7 is the largest cluster
with 32,235 proteins, which corresponds with more than a half of the total amount of
proteins included. Different from the CRPs, few NRPs are included in groups with high
dex and local_nE values, being gathered the majority in low feature values groups.
To validate the less connectivity pattern in NRPs, we have studied how proteins
are classified considering neurological cases and their corresponding normal controls.
Similarly, NRPs are assembled in clusters with the lowest dex and local_nE values
(clusters 1, 3 and 10 with 5.6e-15, 7.8e-31 and 3.1e-24 binomial p-values respectively).
Oppositely clusters 4, 7 and 8 are enriched significantly (7.8e-29, 9.4e-22 and 3.9e-27
mutually) in normal related proteins, representing higher feature values (Figure 4.8).
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Figure 4.8: K-Means clustering analysis in CNS disorder and normal control pro-
teins (a) Proteins by their corresponding dex and local_nE scores after K-Means
clusterization. (b) Pie charts containing the colored fraction of diseases in each
cluster characterized by proteins with similar local_nE and dex values.
112
4.5. Results
4.5.4 Biological outcome
Following the proposed pipeline, once the clusters are obtained, we have ana-
lyzed the biological context behind the classification. To achieve this objective, an
enrichment analysis on the biological pathways has been conducted using GeneCodis
(gen; Carmona-Saez et al., 2007; Nogales-Cadenas et al., 2009; Tabas-Madrid et al.,
2012) for each cluster of proteins. We have conducted in GeneCodis an enrichment
analysis on KEGG pathways of the very connected proteins, and we have observed
that these proteins are significantly enriched in pathways in cancer, focal adhesion,
MAPK signaling pathway, Chemokine signaling pathway, and diverse inflammation
pathways among others. In particular, the deregulation of the p53 signaling pathway
is associated with the initiation and progression of cancer. Interestingly, recent studies
previously point to a role for this pathway in CNS disorders (Tabarés-Seisdedos and
Rubenstein, 2013).
The PIN1 gene has been proposed to be a putative link between the pathogeneses
of cancer and AD (Behrens et al., 2009). Figure 4.9 shows the different scenarios in
Pin1 protein in ovarian cancer and AD. More than 30% of all the Pin1 interacting
partners are expressed and active (red curves) when the ovarian samples are studied.
However, PIN1 gene in AD is not expressed, and hence, no active connections are
found in AD (blue curves). This protein is associated with cell division (Lu, 2004)
and is typically over-expressed in different cancers. Moreover, PIN1 is depleted in AD.
Different studies support the theory that it restores the function of the phosphorylated
tau protein (Lu, 2004), and mouse models in which PIN1 is knocked down present
neurodegenerative phenotypes (Liou et al., 2011).
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Figure 4.9: Neighbor interactions in Pin1 in (a) Alzheimer’s disease and (b) ovarian
cancer. The red Bezier curves represent the active interactions (Equation 1, case 2)
and the blue Bezier curves represent the inactive interactions (Equation 1, cases 2
and 3). The hub corresponds to the Pin1 protein.
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4.6 Discussion
A pattern recognition system is present, in which proteins related with CNS dis-
orders (NRPs) and cancer related proteins (CRPs) are classified. We have defined
two attributes (dex and local_nE) that are capable to categorize in different groups
the majority of the proteins related to cancer or CNS disorders, corresponding with
clusters with high or low feature values. The dex feature is indicative of the number
of neighbors of each protein being expressed, important to estimate how connected
and active proteins are within the PPIN. And we have adopted the local_nE attribute
from our previous work (Ibáñez et al., 2015), which measures the stability of a single
protein in its neighborhood.
We have validated that the definition of these two features are adequate to classify
the proteins into CRP and NRPs, according to them. Successful classifications have
been obtained with Random Tree Forest, J48 and Bayes classifiers. We have performed
two different classification approaches, SOM and K-Means, to validate that our results
do not depend on the methodology, reinforcing the result.
The first significant finding in this study is that protein groups characterized by
high dex and local_nE are significantly enriched in CRPs. This means, that proteins
within these kinds of clusters are well connected and active within the network, and so
are their neighbors. In these clusters, the majority of proteins correspond to codifying
genes highly expressed in ovarian, colon or liver cancer. This observation goes in
the same direction as previous work, in which studies of the network topology shows
that cancer proteins tend to be central within the network, being highly connected
(Jonsson and Bates, 2006; Taylor et al., 2009; Sun and Zhao, 2010; Xia et al., 2011;
Choura and Rebaï, 2012; Xiong et al., 2014). Others such as Jeong et al. (2001), propose
that important proteins for a cell’s survival are highly connected and altering them
might have profound effects on the interaction network. According to the definition
of the local_nE, higher values in this feature represent active connections between
nodes of expressed genes, indicating that any alteration in this node will destabilize
the network.
Moreover, we have validated further this consideration analyzing cancer cases and
normal controls proteins with similar outcome.
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4.6. Discussion
Our second important finding is that conversely, protein groups characterized by
low dex and local_nE are significantly enriched on NRPs. Proteins inside these clusters
are less connected and active within the network, an so their neighbors. Furthermore,
when proteins in CNS disorder cases and normal controls are studied, proteins which
codifying genes are highly expressed in normal cases, correspond majority to the
groups with high scores of dex and local_nE.
Our approach based on the properties of the network (dex and local_nE) appears to
be capable of identifying candidate protein groups potentially associated with cancer
or CNS disorders. The clusters of proteins with higher dex and local_nE values tend
to be composed of cancer-related genes, and those with moderate dex and local_nE
values are usually composed of neurological-related genes. In fact, dex and local_nE
attributes may be considered as a hallmark of the topological properties of the CRP
and NRPs.
These findings are interesting from the point of view of comorbidity studies.
Tabarés-Seisdedos and Rubenstein (2013) and Tabarés-Seisdedos et al. (2011), among
others, put forward the hypothesis that some CNS diseases could affect the risk of
developing some types of cancer. Many reviews have been published on this topic
(Tabarés-Seisdedos and Rubenstein, 2013). Meta-analyses on direct and inverse can-
cer comorbidity in people with CNS diseases have also been conducted.
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5 Conclusions and future work
5.1 General conclusions
Data mining and machine learning techniques are the drivers of this work. We
have proved here that large amount of biological and medical data can be analyzed
integrating advanced computational methods. In the context of the biomedical theme
of inverse comorbidity, we have presented in chapters 2, 3, and 4 three computa-
tional approaches with different purposes. The results of the application of these
proposed strategies show how the application of new methodologies based on data
mining and machine learning techniques can produce progress in specific domains
of biomedicine.
We have analyzed global genome wide transcriptomic data together with a meta-
analysis strategy, and we have further studied complex relations in biological systems
beyond the functioning of the components in isolation. We have investigated the use
of information on interaction networks (i.e., protein interactions) in order to follow
better the relations in complex systems behavior, and to study dynamic aspects. The
use and application of classification methods to assemble specific proteins of cancer
or CNS disorders has turned out to be a relevant approach in the context of this thesis.
In terms of Biology, we have identified for the first time a set of genes and pathways
deregulated in opposite directions in three CNS disorders and three cancer types.
This finding sets the molecular basis of previously described inverse comorbidity
pattern observed at the population level. The identification of those specific genes and
pathways will provide the first clue for follow-up experimental approaches, including
their investigation of their potential relevance as therapeutic strategies.
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To our knowledge, this work represents the first systematic attempt to the identifi-
cation of possible molecular base of inverse comorbidity associations.
In a follow-up study analyzing the addition of information on protein–protein
interaction networks, allowed us to show that cancer related networks are more
unstable than networks associated with neurological disorders. Finally, in a third
study, using SOM, K-Means, and classification systems we have defined two features
that have allowed us to categorize and sort sets of proteins characteristics of each
disorder.
This thesis represents a collaboration between bioinformatics, computational
biology, and artificial intelligence, in which computational methods based on machine
learning techniques have been proposed to better understand the biological context
behind the inverse comorbidity. In previous chapters methodologies, results, and
conclusions corresponding to these three studies have been presented. In this chapter
the principal conclusions are summarized, and future perspectives described.
5.2 Development of a data mining approach to perform
transcriptomic meta-analyses between cancer–CNS
disorders
A relevant number of epidemiological studies have demonstrated a lower-than-
expected probability of developing some types of cancer in patients with certain
CNS disorders (known as inverse comorbidity). This behavior suggests that inverse
comorbidity may be influenced by environmental factors, drugs treatments and other
aspects related with disease diagnosis. Genetics is at the basis of this behavior, and
it regulates and influences to this contribution in combination with external factors.
This adaptation represents an open door to understand why certain individuals are
protected against many different types of cancer. For such aim, our principal objective
was to discover the molecular mechanisms that underlie this apparent protective
effect.
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5.2. Development of a data mining approach to perform transcriptomic
meta-analyses between cancer–CNS disorders
In the first part in this thesis and described in chapter 2, we present a novel data
mining approach in order to compute transcriptomic meta-analyses between some
types of cancer and CNS disorders. We hypothesize that a molecular substrate exists
and is shared in a specific manner in cancer and CNS disorders. Accordingly, we
propose here the deregulation in opposite directions of a common set of genes and
pathways as an underlying cause of inverse comorbidity. Using gene expression data,
our principal idea was to test whether there is a significant overlap between genes
that are up-regulated in cancer and down-regulated in CNS disorders, and the other
way around.
The significant result here is that a significant overlap is observed between the
genes up-regulated in cancers and down-regulated in CNS disorders, and conversely,
between the genes down-regulated in cancers and up-regulated in CNS disorders.
These gene expression deregulations in opposite directions are also observed at the
level of pathways, and point to specific genes and functions the deregulation of which
could promote CNS disorders and simultaneously lowers the initiation or progression
of cancer.
In the future, further analyses will be necessary to conclude to a direct protective
effect of gene expression deregulations in cancer-prone tissues of patients suffer-
ing from CNS disorders. This identification of antagonistically deregulated genes
and pathways in complex diseases that have been previously described as inversely
comorbid provides, to our knowledge, the first systematic insights into the possi-
ble molecular base of these associations, acknowledging previous important works
(Behrens et al., 2009). It suggests that the up-regulation of a set of genes or processes
could increase the incidence of CNS disorders and simultaneously lower the chances
of developing cancers, while the down-regulation of another set of genes or processes
could contribute to a decrease in the incidence of CNS disorders while increasing the
cancer risks.
The post-mortem brain samples in CNS disorders have likely received drug treat-
ments. Hence, the observed expression deregulations could be the consequence of the
drugs administered to the patients. If this is the case, it can be hypothesized that some
of the drugs used to treat CNS disorders might be able to revert the expression of a
number of cancer genes. In this context, the repurposing of drugs from the CNS to the
cancer field could open new therapeutic avenues. Indeed some punctual observations
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have been made. For example, a drug repositioning bioinformatic approach have
identified that triclyclic antidepressant and related molecules could potently induce
apoptosis in small cell lung cancer and other neuroendocrine tumors (Jahchan et al.,
2013). Another example is the thioridazine, an anti-psychotic drug antagonizing the
dopamine receptor and potentially able to alter physiological states and expression
patterns, have been reported to target cancer stem cells selectively (Sachlos et al.,
2012). In the other direction, there is another work presented in the section 2.6, in
which they have proved that a failed drug on treating solid tumor appears to restore
synaptic connections and reduced inflammation, and the animal’s memory, a hall-
mark of Alzheimer’s disease. In this manner, memory and the connections between
brain cells are restored in mice with a model of Alzheimer’s given this experimental
cancer drug (Kaufman et al., 2015).
Despite these two last observations, the effect of the drugs cannot explain by
themselves the observed inverse comorbidity. For instance, several works have noted
that the relatives of patients suffering schizophrenia have less probability of devel-
oping any cancer (Gal et al., 2012; Ji et al., 2013), suggesting that genes associated
with schizophrenia might confer reduced cancer susceptibility. There is a genomic
and molecular base that determines the behavior of the individual in general, and
the effect of the drug in each one, in particular. More data is necessary to be able
to establish a relationship between some drugs and the genetics behind the inverse
comorbidity, and the observed gene expression patterns.
5.3 Development of a machine learning approach inspired
by simulated annealing to study the stability of PPINs
in cancer-CNS disorders
Following the molecular basis underlying the differences between cancers and
neurological conditions, we have integrated here gene expression data with protein–
protein interaction networks to study these differences in terms of network organiza-
tion rather than at the level of individual genes. Molecular networks, and in particular,
protein–protein interaction networks provide a powerful tool for the study of biomedi-
cal systems. Diseases can alter the structure of the network (Ideker and Sharan, 2008),
and it has also be pointed out that they can also alter the stability of networks (Teschen-
dorff and Severini, 2010; West et al., 2012), and studying network stability might be
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5.3. Development of a machine learning approach inspired by simulated
annealing to study the stability of PPINs in cancer-CNS disorders
fundamental to the better understanding of the biological systems behave, apart from
components in isolation. Stability describes a network state that is not significantly
altered, even when fundamental properties have changed or perturbations have been
introduced.
In the second part in this thesis and described in chapter 3, we have designed an
approach inspired on SA, representing PPINs as systems of nodes that are dynamically
updated towards a global state of stability. Our strategy is based on the definition
of a neighbor-energy function (nE) that measures the stability of the network in the
general deterministic approach, where nE indicates network stability, and it can be
interpreted in terms of resistance to alterations and perturbations. We have analyzed
a large set of experimental data on gene expression and various PPINs.
The first significant finding of this study is that networks containing information
about expression in four human cancers (ovarian, colon, kidney, and liver) are less
stable than the control networks of normal samples. Moreover, this instability in the
network seems to increase as these cancers evolve, at least in the tumor progression
data sets analyzed. The approach employed is based on the analyses of samples in
different conditions and it does not include temporal evolution per se. Thus, the
results obtained by analyzing the temporal progression of tumors can be taken as an
indication of network evolution towards a less stable state, and a way of reconciling
our methodology with the standard SA applications.
The second important finding is that the AD network is more stable than the
corresponding control normal network, with a significant increase in the nE of the
corresponding networks. This is an interesting behavior that contrasts with that of
cancers, and as far as we know is detected here for the first time. One possible inter-
pretation of these results would be that cancer implies a general deregulation of cell
growth through the hyper-activation of certain pathways, resulting in a destabilization
of their interactions, while AD and other neurological disorders imply the stabilization
of biological processes and network interactions, and their general slowing down. The
striking contrast in the behavior of cancer and AD networks, from less to more stable
networks, should be considered in the context of the observed inverse comorbidity of
these two groups of diseases.
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5.4 Development of a pattern recognition method for the
recognition between cancer–CNS disorders
related proteins
Studies of the topology of PPINs show that cancer proteins tend to be central within
the network as they are highly connected (Jonsson and Bates, 2006; Taylor et al., 2009;
Sun and Zhao, 2010; Xia et al., 2011; Choura and Rebaï, 2012; Xiong et al., 2014). It has
also been proposed that important proteins for a cell’s survival are highly connected
(Jeong et al., 2001), and altering them has profound effects on the interaction network.
Similarly, studies on the genomic and network characteristics of genes that mutated in
cancer indicate that these genes tend to encode central hubs within a PPIN (Rambaldi
et al., 2008).
In the third section in this thesis and described in chapter 4, following the main
hypothesis and results shown in chapters 2 and 3, we examine critically whether
cancer related proteins (CRPs) tend to be more connected. Indeed, we go further, and
we also analyze whether proteins related with neurological disorders (NRPs) have
the opposite behavior than CRPs, pursuing the inverse comorbidity theory in these
complex disorders. A pattern recognition system is designed for the classification
of NRPs and CRPs. For such objective, we have defined two attributes (dex and
partial_nE) that are capable to categorize in different groups the majority of the
proteins related to cancer or CNS disorders, corresponding with clusters with high or
low feature values. The dex feature is indicative of the number of neighbors of each
protein being expressed, important to estimate how connected and active proteins
are within the PPIN. And we have adopted the local_nE attribute from the previous
study [chapter 3, (Ibáñez et al., 2015)], which measures the stability of a single protein
in its neighborhood.
We have validated that the definition of these two features are adequate to classify
the proteins into CRP and NRPs, according to them. Successful classifications have
been obtained with Random Tree Forest, J48, and Bayes classifiers. We have performed
two different classification approaches, SOM and K-Means, to validate that our results
do not depend on the methodology, reinforcing the result.
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5.4. Development of a pattern recognition method for the recognition
between cancer–CNS disorders related proteins
The first significant finding in this study is that protein groups characterized by
high dex and partial_nE are significantly enriched in CRPs. This means, that proteins
within these kinds of clusters are well connected and active within the network, and so
are their neighbors. In these clusters, the majority of proteins correspond to codifying
genes highly expressed in ovarian, colon or liver cancer. This observation goes in
the same direction as previous work, in which studies of the network topology shows
that cancer proteins tend to be central within the network, being highly connected
(Jonsson and Bates, 2006; Taylor et al., 2009; Sun and Zhao, 2010; Xia et al., 2011;
Choura and Rebaï, 2012; Xiong et al., 2014). Others such as Jeong et al. (2001), propose
that important proteins for a cell’s survival are highly connected and altering them
might have profound effects on the interaction network. According to the definition
of the local_nE, higher values in this feature represent active connections between
nodes of expressed genes, indicating that any alteration in this node will destabilize
the network. Moreover, we have validated further this consideration analyzing cancer
cases and normal controls proteins with similar outcome.
Our second important finding is that conversely, protein groups characterized by
low dex and local_nE are significantly enriched on NRPs. Proteins inside these clusters
are less connected and active within the network, an so their neighbors. Furthermore,
when proteins in CNS disorder cases and normal controls are studied, genes highly
expressed (which codify proteins) in normal cases, are majority in groups with high
scores of dex and partial_nE.
Our system based on the properties of the network (dex and local_nE) appears to
be capable of identifying candidate protein groups potentially associated with cancer
or CNS disorders. The clusters of proteins with higher dex and local_nE values tend
to be composed of cancer-related genes, and those with moderate dex and local_nE
values are usually composed of neurological-related genes. In fact, dex and local_nE
attributes may be considered as a hallmark of the topological properties of the CRP
and NRPs. These findings are interesting from the point of view of comorbidity studies.
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5.5 Future directions
The analysis of opposite expression deregulations in cancer and CNS disorders
can be considered as an initial step toward a more exhaustive understanding of the
inverse comorbidity, and the approach we here present could serve as a new strat-
egy to investigate further possible relations between other complex diseases [for a
disease comorbidities review see (Catalá-López et al., 2014b)]. Further analyses will
be necessary to see whether this kind of gene expression relations take part in more
future available data. Regarding the protective effect, since gene regulation change the
phenotype, it could explain the protection against a disease; but additional complex
and systematic experiments should be done.
The computational approach inspired on the DSA to analyze PPIN stability in
complex disorders could be used in the characterization of many samples in cancer
evolution, and validate it further with a clinical confirmation step (i.e., correlate the
cancer stage with the corresponding sample nE, according to the nE evolution within
that cancer study). It could also be used as a classifier to distinguish cancer and
normal samples. Another possibility will be to cluster the results of this procedure
in order to extract specific proteins for which additional experimental information
could be available. Furthermore, this scheme could be also applied to any network
system where the elements are characterized by a state Si and their interactions
associated to a weight Wi j . In a biological context there are numerous systems with
these characteristics, such as protein interaction and gene control networks. In
particular, it could be interesting to apply into a protein–protein interaction network,
in which different drugs are introduced, and analyze the system behaviors (defining
properly the parameters).
The expert system for classifying proteins related with cancer and neurological dis-
orders, could be used to classify and characterize proteins that are strongly conserved
in cancer evolution from the point of view of the connectivity within the network.
Moreover, it could be considered as an initial example toward the characterization of
proteins related with other complex disorders, estimating how connected and active
proteins are within the PPIN, as well as measuring the stability of each protein in its
neighborhood. This strategy could help ranking a set of candidate proteins or genes,
that might play a key role within certain complex disorders.
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A Supplementary Figures
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Figure A.1: Comparisons of DEGs associated with CNS disorders and cancers at
0.005. The DEGs up- and down-regulated after gene expression meta-analysis
in each CNS disorder (Alzheimer’s Disease, AD; Parkinson’s Disease, PD; and
Schizophrenia, SCZ) and in each Cancer (Colorectal Cancer, CRC; Prostate Cancer,
PC; Lung Cancer, LC) are compared to each others.
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q-value
0 0.05
Figure A.2: Comparisons of DEGs associated with CNS disorders and cancers at
0.0005. The DEGs up- and down-regulated after gene expression meta-analysis
in each CNS disorder (Alzheimer’s Disease, AD; Parkinson’s Disease, PD; and
Schizophrenia, SCZ) and in each Cancer (Colorectal Cancer, CRC; Prostate Cancer,
PC; Lung Cancer, LC) are compared to each others.
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Figure A.3: Comparisons of DEGs associated with CNS disorders and cancers at
0.00005. The DEGs up- and down-regulated after gene expression meta-analysis
in each CNS disorder (Alzheimer’s Disease, AD; Parkinson’s Disease, PD; and
Schizophrenia, SCZ) and in each Cancer (Colorectal Cancer, CRC; Prostate Cancer,
PC; Lung Cancer, LC) are compared to each others.
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q-value
0 0.05
Figure A.4: Comparisons of DEGs associated with CNS disorders and cancers at
0.000005. The DEGs up- and down-regulated after gene expression meta-analysis
in each CNS disorder (Alzheimer’s Disease, AD; Parkinson’s Disease, PD; and
Schizophrenia, SCZ) and in each Cancer (Colorectal Cancer, CRC; Prostate Cancer,
PC; Lung Cancer, LC) are compared to each others.
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Figure A.5: Biocarta pathway significantly deregulated in the three types of cancers
and CNS disorders. Cancer upregulated (yellow), cancer downregulated (blue),
CNS disorder upregulated (green) and CNS disorder downregulated (red). The
green/blue and yellow/red associations thus correspond to pathways deregulated in
opposite directions in CNS disorders and cancers.
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Figure A.6: Reactome pathway significantly deregulated in the three types of can-
cers and CNS disorders. Cancer upregulated (yellow), cancer downregulated (blue),
CNS disorder upregulated (green) and CNS disorder downregulated (red). The
green/blue and yellow/red associations thus correspond to pathways deregulated in
opposite directions in CNS disorders and cancers.
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B Supplementary material - Network
stability study
B.1 Description of the deterministic simulated
annealing algorithm
Begin i ni t i al i ze nE , Wi j , Si , S j , i , j = 1..N t = 0
do t = t +1
nE =−∑Ni=1∑Nj=1 Wi j ∗Si ∗S j
t = t +1 until t = tmax end
whereas:
nE is the system’s final energy. t corresponds to a gene expression sample in each
dataset and type (Normal, Cancer, Neurological). Wi j describes the weight explained
in Equation 3.1, representing the existing influence between nodes Si and S j . In our
approach Si is the significance level of the expression or no expression of each gene.
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Figure B.1: The nE distribution that maps all the genes in the HPRD network in the:
(a) normal (N) and cancer (C) states (Ovarian, Colon, Liver and Kidney); (b) Normal
(N) and AD (C); (c) Normal (N) and SCZ disease (C) state. The Wilcoxon-rank p-
value is presented below the x-axis.
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B.1. Description of the deterministic simulated annealing algorithm
Figure B.2: The nE distribution that maps all the genes in the HIPPIE network in
the: (a) normal (N) and cancer (C) states (Ovarian, Colon, Liver and Kidney); (b)
Normal (N) and AD (C); (c) Normal (N) and SCZ disease (C) state. The Wilcoxon-
rank p-value is presented below the x-axis.
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